Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 1432. Отображено 194.
25-08-2021 дата публикации

КУЛЬТУРАЛЬНАЯ СРЕДА КЛЕТОК-ПРЕДШЕСТВЕННИКОВ КОЖИ, ПРОИСХОДЯЩИХ ИЗ СТВОЛОВЫХ КЛЕТОК, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ

Номер: RU2754043C2

Изобретение относится к области генетической технологии и медицине. Предложены способ получения кондиционированной среды эпидермальных клеток-предшественников, происходящих из стволовых клеток, включающий дифференцировку стволовых клеток, не являющихся стволовыми клетками, полученными из человеческих эмбрионов, в эпидермальные клетки-предшественники в среде для дифференцировки, содержащей аскорбиновую кислоту и гидрокортизон, затем их культивирование в среде и извлечение полученной кондиционированной среды эпидермальных клеток-предшественников; кондиционированная среда эпидермальных клеток-предшественников, происходящих из стволовых клеток, полученная указанным способом, и способ получения белка из эпидермальных клеток-предшественников, происходящих из указанных стволовых клеток, где белок включает один или более белков, выбранных из TSP, TIMP1, TIMP2, EDA-A2, XEDAR, Ангиопоэтина-1, SPARC, TMEFF1/Томорегулина-1, Нидогена-1, IGFBP-3, TRANCE и IL-15R альфа. 3 н. и 16 з.п. ф-лы, 8 ил, 3 табл ...

Подробнее
27-12-2018 дата публикации

TREATMENT AGENT FOR EPIDERMOLYSIS BULLOSA

Номер: CA0003067963A1
Принадлежит: SMART & BIGGAR LLP

Provided is a cell preparation for treating epidermolysis bullosa, containing SSEA-3 positive pluripotent stem cells (muse cells) derived from a mesenchymal tissue of a live body or cultured mesenchymal cells. The epidermolysis bullosa is preferably epidermolysis bullosa simplex, junctional epidermolysis bullosa, or dystrophic epidermolysis bullosa.

Подробнее
09-03-2017 дата публикации

THREE DIMENSIONAL HYDROGELS FOR CULTURING ORGANOIDS

Номер: CA0002997375A1
Принадлежит:

The invention provides hydrogels and methods for three-dimensional (3D) culture of adult epithelial stem cells and uses thereof.

Подробнее
15-09-2011 дата публикации

AMELIORATING OR THERAPEUTIC AGENT FOR CHRONIC PROSTATITIS, INTERSTITIAL CYSTITIS AND/OR URINATION DISORDERS

Номер: CA0002792085A1
Принадлежит:

The purpose of the present invention is to provide a medicament which is useful for amelioration or treatment of chronic prostatitis, interstitial cystitis and/or urination disorders. Specifically, the present invention relates to a novel pharmaceutical use of an extract from inflamed tissue inoculated with vaccinia virus, and relates to an ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders, said agent containing the extract as an active ingredient. The medicament of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders.

Подробнее
24-03-2020 дата публикации

IMMORTALIZATION OF EPITHELIAL CELLS AND METHODS OF USE

Номер: CA0002817712C
Принадлежит: UNIV GEORGETOWN, GEORGETOWN UNIVERSITY

The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing.

Подробнее
15-04-2016 дата публикации

Composition for increasing the proliferation of dermal papilla cells and the pharmaceutical combination and the manufacturing method thereof.

Номер: CH0000710157A2
Принадлежит:

Die vorliegende Erfindung stellt eine Zusammensetzung zur Vergrösserung der Proliferation von Hautpapillenzellen bereit. Die Zusammensetzung wird erhalten basierend auf dem Kultivieren von Zellen, für eine bestimmte Anzahl an Tagen, auf einem serumfreien Medium, um Zytokine zu erhalten. Die gewonnenen Zellen werden beschädigt unter Verwendung von multiplen Gefrier-Auftau-Zyklen, um eine grössere Menge an Polypeptidmischungen zu erhalten, welche weiter konzentriert und entsalzt werden, um eine Zusammensetzung mit spezifischen Molekulargewichten zu erhalten, wobei die Zusammensetzung eine, die Proliferation von Hautpapillenzellen, mit einer erhöhten Rate von ungefähr 5% bis 50%, vergrössernde Wirkung besitzt.

Подробнее
15-06-2020 дата публикации

Composition for increasing the proliferation of dermal papilloma cells and the pharmaceutical combination and process for the preparation thereof.

Номер: CH0000710157B1
Принадлежит: BIONET COPR, BIONET COPR.

Die vorliegende Erfindung stellt eine Zusammensetzung zur Vergrösserung der Proliferation von Hautpapillenzellen bereit. Die Zusammensetzung wird erhalten basierend auf dem Kultivieren von Zellen, für eine bestimmte Anzahl an Tagen, auf einem serumfreien Medium, um Zytokine zu erhalten. Die gewonnenen Zellen werden beschädigt unter Verwendung von multiplen Gefrier-Auftau-Zyklen, um eine grössere Menge an Polypeptidmischungen zu erhalten, welche weiter konzentriert und entsalzt werden, um eine Zusammensetzung mit spezifischen Molekulargewichten zu erhalten, wobei die Zusammensetzung eine, die Proliferation von Hautpapillenzellen, mit einer erhöhten Rate von ungefähr 5% bis 50%, vergrössernde Wirkung besitzt.

Подробнее
30-03-2016 дата публикации

Serum-free medium containing PDGF for DS cells

Номер: CN0105452441A
Принадлежит:

Подробнее
14-12-2018 дата публикации

Cell line based on low-dose nano-TiO2 induction, and preparation method and application thereof

Номер: CN0108998407A
Автор: WANG HUI, BA QIAN, JIA XUDONG
Принадлежит:

Подробнее
04-07-2017 дата публикации

인간 피부 진피 유래 성체 줄기세포

Номер: KR0101751355B1
Принадлежит: (주)아모레퍼시픽

... 본 발명은 인간 피부 진피로부터 유래한 성체 줄기세포 및 그의 분리방법을 제공한다. 또한, 본 발명은 상기 인간 피부 진피 유래 성체 줄기세포에서 분화된 골아세포 또는 지방세포 및 그의 분화방법을 제공한다. 또한, 상기 줄기세포, 골아세포 또는 지방세포를 포함하는 골 생성용 또는 지방생성용 조성물을 제공한다. 본 발명의 분리방법은 피부 진피 유래 성체 줄기세포를 쉽고 간단하며, 고수득율로 확보할 수 있게 하고, 상기 방법으로 분리된 피부 진피 유래 성체 줄기세포에서 특이적으로 발현하는 유전자 및 성장 인자를 추후 분리 및 동정하여 이용할 수 있다.

Подробнее
14-04-2016 дата публикации

COMPOSITION FOR CULTURING CELL AND PROMOTING CELL PROLIFERATION, COMPRISING SCLAREOL

Номер: KR1020160040347A
Принадлежит:

The present invention relates to a composition comprising sclareol which is a novel bioactive substance. The present invention can be used as a composition for promoting cell proliferation and for culturing cells substituting for animal serum, and a composition for reducing skin wrinkles, inhibiting skin aging, alleviating skin elasticity, and regenerating wounds or skin. COPYRIGHT KIPO 2016 (AA) Sclareol (BB) General shape observation ...

Подробнее
24-12-2018 дата публикации

LGR4, LGR5 및 LGR6 발현 상피 줄기 세포를 사용한 조직 응용에서의 최소 극성화 기능 세포 미소응집체 유닛의 개발 및 사용 방법

Номер: KR1020180136588A
Автор: 로크 덴버 엠.
Принадлежит:

... 본 발명은 상처 치료 용도, 조직 공학적 처리, 세포 치료 용도, 재생 의학 용도, 의학/치료 용도, 조직 치유 용도, 면역 치료 용도 및 조직 이식 치료 용도를 위한, 바람직하게는 직접 적용을 위한 전달 벡터/기질/지지체/스캐폴드와 관련된 류신이 풍부한 반복체-함유 G-단백질 결합 수용체 (LGR) 발현 세포를 함유하는 미소응집체 다세포 최소 극성화 이식편의 구조물에 관한 것이다.

Подробнее
30-01-2020 дата публикации

STEM CELL-DERIVED SKIN PRECURSOR CELL CULTURE MEDIUM AND PREPARATION METHOD THEREFOR

Номер: SG11201913778VA
Принадлежит:

Подробнее
03-05-2018 дата публикации

MESENCHYMAL STEM CELLS-HYDROGEL-BIODEGRADABLE OR MESENCHYMAL STEM CELLS-HYDROGEL-NONDEGRADABLE SUPPORT COMPOSITION FOR ALLEVIATING OR IMPROVING EPIDERMOLYSIS BULLOSA

Номер: US20180117217A1
Автор: Sung-Koo LEE, Mihyung KIM
Принадлежит:

Provided are a composition and a sheet, including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support and a preparing method thereof. More specifically, in the sheet including a mesenchymal stem cells-hydrogel-biodegradable support or a mesenchymal stem cells-hydrogel-nondegradable support according to the present invention, the high-active mesenchymal stem cells may be applied to a wounded part of a patient with epidermolysis bullosa as it is without isolation using proteases, and in the culturing, an extracellular matrix such as collagen, laminin, fibronectin, and elastin secreted from the mesenchymal stem cells is wholly present on the hydrogel to have an advantageous effect that skin reproduction and re-epithelization abilities are significantly excellent as compared with conventional dressing agents used for epidermolysis bullosa. 1. A preparing method of a sheet for alleviating or improving epidermolysis bullosa , the method comprising:(a) obtaining a mesenchymal stem cells-hydrogel-support by attaching mesenchymal stem cells to (i) at least one kind of support selected from the group consisting of biodegradable supports and nondegradable supports; (ii) at least two kinds of nondegradable supports; or (iii) a combination of at least one kind of support and at least one kind of nondegradable support using a hydrogel; and(b) culturing the mesenchymal stem cells-hydrogel-support obtained in step (a) in a growth medium,wherein the growth medium is a medium including fetal bovine serum (FBS) and at least one factor selected from the group consisting of a basic fibroblast growth factor (bFGF), an epidermal growth factor (EGF), a transforming growth factor (TGF-beta1), a platelet-derived growth factor (PDGF), a vascular endothelial growth factor (VEGF), a hepatocyte growth factor (HGF) and an insulin-like growth factor (IFG-1), the hydrogel is at least one selected from the group consisting of fibrin glue ...

Подробнее
21-02-2017 дата публикации

Способ получения препарата на основе стволовых клеток, выделенных из ткани селезенки свиней, для профилактики и лечения инфекционных и незаразных болезней домашних и сельскохозяйственных животных

Номер: RU2611205C1

Изобретение относится к области клеточной биотехнологии и биофармакологии, конкретно к получению препарата на основе стволовых клеток, выделенных из ткани селезенки свиней, для профилактики и лечения инфекционных и незаразных болезней домашних и сельскохозяйственных животных. Изобретение может найти применение в ветеринарии для лечения и профилактики широкого круга заболеваний домашних и сельскохозяйственных животных. Способ включает введение в клеточно-культуральную среду, полученную из измельченной ткани селезенки свиней, обработанной 0,5%-ным раствором метронидазола и 0,05%-ным раствором хлоргексина с последующими дезагрегацией ее 0,25%-ным раствором трипсина и культивированием клеточного материала с концентрацией клеток 1,5⋅10-2,0⋅10на 1 мл ростовой среды Игла-MEM с добавлением 10-15% эмбриональной сыворотки крупного рогатого скота в присутствии стимулятора роста клеточных культур Пинексида, препарата «Повин ВМ», в состав которого входят водный раствор полиэтиленгликоля, водный раствор ...

Подробнее
18-08-2020 дата публикации

Номер: RU2018140838A3
Автор:
Принадлежит:

Подробнее
27-04-2012 дата публикации

КОМБИНАЦИЯ ХИМИЧЕСКОГО И ГЕНЕТИЧЕСКОГО ПОДХОДОВ К ПОЛУЧЕНИЮ ИНДУЦИРОВАННЫХ ПЛЮРИПОТЕНТНЫХ СТВОЛОВЫХ КЛЕТОК

Номер: RU2010139426A
Принадлежит:

... 1. Способ получения индуцированных плюрипотентных стволовых клеток неплюрипотентных клеток млекопитающего in vitro или ex vivo, включающий а) приведение указанных клеток в контакт по меньшей мере с одним из: ! агента, ингибирующего метилирование H3К9 или способствующего деметилированию H3К9; ! агониста кальциевых каналов L-типа; ! активатора пути цАМФ; ! ингибитора ДНК-метилтрансферазы (DNMT); ! лиганда ядерного рецептора; ! ингибитора GSK3; ! ингибитора МЕК; ! ингибитора рецептора TGFβ/ALK5; ! ингибитора HDAC; и ! ингибитора Erk, ! с получением индуцированных плюрипотентных стволовых клеток. ! 2. Способ по п.1, включающий ! введение одного или более экзогенных полипептидов, выбранных из группы, состоящей из полипептида KIf, полипептида Oct, полипептида Мус и/или полипептида Sox, в неплюрипотентные клетки. ! 3. Способ получения индуцированных плюрипотентных стволовых клеток из неплюрипотентных клеток млекопитающего in vitro или ex vivo, включающий ! a) введение одного или более экзогенных ...

Подробнее
07-06-2017 дата публикации

Engineered skin equivalent, method of manufacture thereof and products derived therefrom

Номер: GB0201706380D0
Автор:
Принадлежит:

Подробнее
03-07-2019 дата публикации

Improved culture method using integrin agonist

Номер: GB0201906978D0
Автор:
Принадлежит:

Подробнее
21-09-2017 дата публикации

COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE VII COLLAGEN DEFICIENCIES

Номер: CA0003017757A1
Принадлежит:

The present invention relates to self-inactivating lentiviral vectors comprising the COL7A1 gene or a functional variant thereof and its use in a method for the treatment of Type VII collagen deficiency, such as dominant dystrophic epidermolysis and recessive dystrophic epidermolysis.

Подробнее
27-02-2014 дата публикации

METHOD FOR ISOLATION AND PURIFICATION OF EPITHELIAL STEM CELLS FROM SKIN

Номер: CA0002882677A1
Принадлежит:

The current invention concerns a method for obtaining a cellular composition comprising epithelial stem cells (EpSCs) from mammalian skin, whereby said composition comprises at least 90% of viable EpSCs, comprising the steps of: - obtaining a mammalian skin sample; - obtaining a cell suspension from said skin sample by performing at least one enzymatic dissociation step; and - culturing said cell suspension under low-attachment conditions. Preferably cellular composition comprises epithelial stem cells derived from the epidermal layer. In a second aspect, the current invention provides for a cellular composition obtained by the method according to the invention.

Подробнее
30-05-2019 дата публикации

Номер: KR0101984074B1
Автор:
Принадлежит:

Подробнее
16-05-2013 дата публикации

LONG LASTING DRUG FORMULATIONS

Номер: WO2013069016A2
Принадлежит:

The present invention is directed to long-lasting erythropoietin therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes erythropoietin.

Подробнее
17-10-2013 дата публикации

MULTIPOTENT STEM CELL-BASED CULTURE SYSTEMS AND MODELS

Номер: US20130274114A1
Автор: LEONARD SCIORRA
Принадлежит: SAINT PETER'S UNIVERSITY

This invention generally relates to multipotent stem cell-based research tools. More particularly, the present invention relates to culture systems and 3-dimensional tissue models that may be used for identifying agents useful for treating diseases and conditions and that are suitable for high throughput screening applications. This present invention is based, in part, on the discovery of a method for propagating multipotent stem cells from human skin fibroblasts and subsequently differentiating those multipotent stem cells into cells of any of the three germ layers. Aspects of the invention include drug discovery tools as a high throughput screen; 3-dimensional tissue engineering model, and drug discovery tools thereof; research tools for identifying genes that are important for acquiring multipotency and for identifying genes that are important for lineage-specific differentiation, and drug discovery tools thereof; diagnostic tools for identifying defective genes; and autologous therapies based on the propagated multipotent stem cells.

Подробнее
03-09-2014 дата публикации

ABC5 positive mesenchymal stem cells as immunomodulators

Номер: EP2772535A1
Автор: Frank, Markus, H
Принадлежит:

The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

Подробнее
27-07-2006 дата публикации

СРЕДСТВО ДЛЯ ИЗМЕНЕНИЯ СКОРОСТИ РОСТА ИЛИ РЕПРОДУКЦИИ КЛЕТОК, СПОСОБ ЕГО ПОЛУЧЕНИЯ, СПОСОБ СТИМУЛЯЦИИ ЗАЖИВЛЕНИЯ РАН ИЛИ ЛЕЧЕНИЯ ОЖОГОВ, СПОСОБ КОРРЕКЦИИ КОСМЕТИЧЕСКОГО ДЕФЕКТА, СПОСОБ ИНГИБИРОВАНИЯ СТАРЕНИЯ КОЖИ И СПОСОБ СТИМУЛЯЦИИ РОСТА ВОЛОС

Номер: RU2280459C2
Принадлежит: СКИНМЕДИКА, ИНК. (US)

Изобретение относится к области биотехнологии. Средство содержит кондиционированную культуральную среду, полученную при культивировании эукариотических клеток в трех измерениях. Способ получения средства предусматривает: а) получение кондиционированной клеточной среды культивирования, содержащей требуемые уровни внеклеточных продуктов, путем культивирования эукариотических клеток в трех измерениях в клеточной культуральной среде in vitro; b) отделение кондиционированной клеточной среды культивирования от клеток, использованных для кондиционирования указанной среды; и, в случае необходимости, с) объединение указанной кондиционированной клеточной среды культивирования с фармацевтически приемлемым носителем. Средство используют для стимуляции заживления ран или лечения ожогов, коррекции косметического дефекта, ингибирования старения кожи и стимуляции роста волос. Изобретение позволяет модулировать скорость роста и репродукции эукариотических клеток. 6 с. и 31 з.п. ф-лы, 2 табл., 5 ил.

Подробнее
01-04-2024 дата публикации

КУЛЬТУРАЛЬНАЯ СРЕДА ДЛЯ ЭПИТЕЛИАЛЬНЫХ КЛЕТОК ПЛОСКОКЛЕТОЧНОЙ КАРЦИНОМЫ ПИЩЕВОДА, СПОСОБ КУЛЬТИВИРОВАНИЯ И ИХ ПРИМЕНЕНИЕ

Номер: RU2816529C1

Настоящее изобретение относится к области биотехнологии. Изобретение раскрывает новую культуральную среду, содержащую ингибиторы киназы MST1/2 и киназы ROCK и обеспечивающую более короткий период культивирования клеток в сравнении с известными аналогами. Изобретение может быть применимо для культивирования или размножения in vitro эпителиальных клеток первичной плоскоклеточной карциномы пищевода. Клеточная модель, полученная с применением культуральной среды для первичных клеток, согласно настоящему изобретению может быть использована для оценки эффективности и скрининга лекарственных средств, подходящих для лечения рака пищевода. 4 н. и 10 з.п. ф-лы, 14 ил., 9 табл., 8 пр.

Подробнее
20-01-2005 дата публикации

КОМПОЗИЦИИ, СОДЕРЖАЩИЕ КОНДИЦИОНИРОВАННУЮ КЛЕТОЧНУЮ КУЛЬТУРАЛЬНУЮ СРЕДУ, И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ

Номер: RU2001133453A
Принадлежит:

... 1. Фармацевтическая композиция, содержащая кондиционированную клеточную культуральную среду, где указанная среда включает среду, которая ранее поддерживала рост эукариотических клеток, культивированных в трех измерениях, и фармацевтический носитель. 2. Фармацевтическая композиция по п.1, где кондиционированная клеточная культуральная среда имеет форму жидкой среды, твердой среды, лиофилизованной среды, порошка, геля или пленки. 3. Фармацевтическая композиция по п.1, где композиция имеет пониженное или повышенное содержание одного или нескольких внеклеточных продуктов, происходящих от указанной кондиционированной среды, при помощи методов разделения белков, включая иммуноаффинную хроматографию, гель-хроматографию, ионообменную хроматографию, аффинную хроматографию на хелате металла, ВЭЖХ-очистку и гидрофобную хроматографию. 4. Фармацевтическая композиция по п.3, где внеклеточным(и) продуктом (ами) является белок внеклеточного матрикса. 5. Фармацевтическая композиция по п.3, где внеклеточным ...

Подробнее
20-12-2006 дата публикации

Methods relating to pluripotent cells

Номер: GB0000622395D0
Автор:
Принадлежит:

Подробнее
04-10-2018 дата публикации

Compositions and methods for treatment of type VII collagen deficiencies

Номер: AU2017233055A1
Принадлежит: Shelston IP Pty Ltd.

The present invention relates to self-inactivating lentiviral vectors comprising the ...

Подробнее
14-10-2021 дата публикации

Highly functional manufactured ABCB5+ mesenchymal stem cells

Номер: AU2020248464A1
Принадлежит:

Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5- positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.

Подробнее
30-12-2015 дата публикации

CULTURED MAMMALIAN LIMBAL STEM CELLS, METHODS FOR GENERATING THE SAME, AND USES THEREOF

Номер: CA0002953524A1
Принадлежит:

The invention provides an isolated limbal stem or progenitor cell (LSC) population or LSC- like population comprising a chemically synthesized, recombinant or isolated nucleic acid encoding PAX6 mtegrated into a chromosome, or alternatively, not integrated remaining as an extrachromosomal genetic material, wherein the isolated LSC population is substantially free of non-LSC cells or wherein the LSC-like population is substantially free of non- LSC-like cells, or wherein the isolated LSC or LSC-like population is substantially free of non-LSC and non-LSC-like cells and uses thereof.

Подробнее
02-04-2019 дата публикации

AMELIORATING OR THERAPEUTIC AGENT COMPRISING AN EXTRACT FROM INFLAMED TISSUE INOCULATED WITH VACCINIA VIRUS FOR CHRONIC PROSTATITIS, INTERSTITIAL CYSTITIS AND/OR URINATION DISORDERS

Номер: CA0002792085C

The purpose of the present invention is to provide a medicinal agent which is useful for amelioration or treatment of chronic prostatitis, interstitial cystitis and/or urination disorders. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and more particularly, it relates to an ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders containing the extract as an active ingredient. The medicinal agent of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders.

Подробнее
07-12-2018 дата публикации

Applications of Wnt signal pathway and activator of Wnt signal pathway

Номер: CN0108949667A
Автор: SUN TIANJUN
Принадлежит:

Подробнее
05-04-2019 дата публикации

Preparation method and application of melanin cellular fluid

Номер: CN0109576213A
Принадлежит:

Подробнее
03-01-2020 дата публикации

CELL AND TISSUE MODELS COMPRISING FIBROBLASTS OF THE DERMO-HYPODERMIC JUNCTION AND APPLICATIONS THEREOF

Номер: FR0003083246A1
Автор: HAYDONT VALERIE
Принадлежит:

Подробнее
07-12-2018 дата публикации

수포성 표피박리증 완화 또는 개선용 중간엽줄기세포-하이드로겔-생분해성 또는 중간엽줄기세포-하이드로겔-비분해성 지지체 조성물

Номер: KR0101926331B1
Автор: 이성구, 김미형
Принадлежит: (주)안트로젠

... 본 발명은 중간엽줄기세포-하이드로겔-생분해성 지지체 또는 중간엽줄기세포-하이드로겔-비분해성 지지체를 포함하는 조성물, 시트 및 이의 제조 방법에 관한 것으로서 보다 구체적으로 본 발명에 따른 중간엽줄기세포-하이드로겔 생분해성 또는 비분해성 지지체를 함유하는 시트는 단백질 분해효소를 이용한 단리과정 없이 고활성의 줄기세포가 그대로 수포성 표피박리증 환자의 환부에 적용될 수 있고, 배양 단계에서 중간엽줄기세포로부터 분비되는 콜라겐, 라미닌, 피브로넥틴, 엘라스틴과 같은 세포외기질이 온전하게 하이드로겔에 첩포되어 존재함으로써 수포성 표피박리증에 사용되던 종래 드레싱제에 비하여 피부 재생 및 재상피화 능력이 현저히 우수한 유리한 효과를 나타낸다.

Подробнее
15-10-2019 дата публикации

Methods and products for transfection

Номер: US0010443045B2

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

Подробнее
18-01-2022 дата публикации

Способ оценки противопсориатического действия наружного препарата на лабораторной модели имиквимод-индуцированного псориаза

Номер: RU2764549C1

Настоящее изобретение относится к клеточной биологии и медицине, в частности к дерматологии, и раскрывает способ оценки противопсориатического действия наружного препарата на лабораторной модели имиквимод-индуцированного псориаза. Для осуществления указанного способа проводят иммуногистохимическое исследование биоптата пораженного участка кожи. Далее с помощью светового микроскопа определяют количество CD3+ и Ki-67+-клеток в пораженной коже. При этом одновременное уменьшение количества CD3+ и Ki-67+-клеток в 2 раза и более по сравнению с контрольной группой является критерием эффективного противопсориатического действия препарата. Настоящее изобретение позволяет повысить точность, достоверность, эффективность и воспроизводимость исследований кожи больных бляшечным псориазом, а также обладает упрощенной методикой со сниженной стоимостью её проведения по сравнению с известными ранее методиками. 3 ил., 1 табл., 2 пр.

Подробнее
30-07-2021 дата публикации

Номер: RU2020103760A3
Автор:
Принадлежит:

Подробнее
05-06-2019 дата публикации

Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using LGR4, LGR5 and LGR6

Номер: GB0002569056A
Принадлежит:

Constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which are associated with a delivery vector, substrate, support, or scaffold for direct application.

Подробнее
04-12-2014 дата публикации

Combined chemical and genetic approaches for generation of induced pluripotent stem cells

Номер: AU2009225665B2
Принадлежит:

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Подробнее
20-11-2014 дата публикации

Methods for using autologous fibroblasts to alter skin identiy

Номер: AU2013256418A1
Принадлежит:

The present invention relates to the field of autologous fibroblasts. More specifically, the present invention provides methods and compositions comprising autologous fibroblasts and uses thereof to alter skin identity. In certain embodiments, volar fibroblasts can be expanded for the ability to induce volar skin at the stump site in amputees. In other embodiments, fibroblasts from haired scalp can be expanded to ameliorate alopecias.

Подробнее
28-09-2017 дата публикации

Method for producing reprogrammed derivative neuronal stem cell from non-neuronal cell by using HMGA2

Номер: AU2014250190B2
Принадлежит: WRAYS PTY LTD

The present invention relates to a method for producing a reprogrammed derivative neuronal stem cell from a differentiated cell. A method for producing a derivative neuronal stem cell according to the present invention can produce a derivative neuronal stem cell from a non-neuronal cell only by using two derivative factors of SOX2 and HMGA2, and so is more effective compared to the conventional method using 4 derivative factors or 5 derivative factors. Also the method considerably enhances the derivation efficiency and proliferation capability compared to the method using only one derivative fact of SOX2, thus enlarging the applicability of the stem cell to treating diseases.

Подробнее
03-01-2017 дата публикации

COMBINED CHEMICAL AND GENETIC APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS

Номер: CA0002718904C

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Подробнее
26-09-2013 дата публикации

CELL SUSPENSION AND USE THEREOF

Номер: CA0002874091A1
Принадлежит:

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration.

Подробнее
23-03-2016 дата публикации

METHODS AND PRODUCTS FOR TRANSFECTION

Номер: CN0105420232A
Принадлежит:

Подробнее
07-03-2013 дата публикации

HUMAN SKIN DERMIS-DERIVED ADULT STEM CELLS CAPABLE OF EXPRESSING A SPECIFIC GENE AND GROWTH FACTORS AS A BIOMARKER

Номер: KR1020130022484A
Принадлежит:

PURPOSE: A human skin dermis-derived adult stem cell is provided to identify and isolate a specific gene and growth factors. CONSTITUTION: A human skin dermis-derived adult stem cell has a gene which is overexpressed and is selected from a group consisting of Sox2(SRY(sex determining region Y)-box 2) and S100b(S100 calcium binding protein B). The stem cells are obtained by sub-culturing human skin dermis-derived fibroblast, reacting on gelatin or type 4 collagen for 1-5 minutes, and isolating cells which adhere to gelatin or type 4 collagen. COPYRIGHT KIPO 2013 [Reference numerals] (AA) Relative expression of Sox2; (BB,EE,HH,KK) Dermis-derived fibroblast; (CC,FF,II,LL) Dermis-derived adult stem cell; (DD) Relative expression of S100b; (GG) Relative expression of Vimentin; (JJ) Relative expression of Nestin ...

Подробнее
10-04-2014 дата публикации

SEBOCYTE CELL CULTURING AND METHODS OF USE

Номер: WO2014055815A1
Принадлежит:

Methods of culturing sebocyte cells, isolated populations of sebocytes, and methods of using the cultured sebocyte cells for screening compounds that inhibit or activate lipogenesis are provided.

Подробнее
22-06-2021 дата публикации

Cell having ability to form stratified epithelial tissue, and method for producing same

Номер: US0011041146B2
Принадлежит: KURITA MASAKAZU, Kurita Masakazu

To convert directly from a somatic cell into a cell having the ability to form stratified epithelial tissue that can act as outer skin of the body, a method for producing a cell having the ability to form stratified epithelial tissue is provided, the method including the step of introducing into a somatic cell at least one gene expressed relatively strongly in a cell having the ability to form stratified epithelial tissue.

Подробнее
02-03-2017 дата публикации

CONDITIONED CELL CULTURE MEDIUM COMPOSITIONS AND METHODS OF USE

Номер: US20170055561A1
Принадлежит:

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium. 1. A conditioned medium for making a composition suitable for topical application , the conditioned medium made by a process comprising the steps of:(a) inoculating fetal fibroblasts or embryonic stem cells onto a substrate in a nutrient medium;(b) culturing the fetal fibroblasts or embryonic stem cells in a two dimensional culture so that the fetal fibroblasts or embryonic stem cells secrete a growth factor and a collagen into the nutrient medium, until the nutrient medium becomes a conditioned medium; and(c) removing the conditioned medium from the cultured cells.2. The conditioned medium for making a composition suitable for topical application of claim 1 , wherein the growth factor is keratinocyte growth factor.3. The conditioned medium for making a composition suitable for topical application of claim 1 , wherein the substrate comprises beads.4. The conditioned medium for making a composition suitable for topical application of claim 1 , wherein during the culturing step the fetal fibroblasts or embryonic stem cells are subjected to hypoxic stress to thereby increase the secretion of the growth factor.5. The ...

Подробнее
30-04-2015 дата публикации

MICRO-ORGANS PROVIDING SUSTAINED DELIVERY OF A THERAPEUTIC POLYPEPTIDE AND METHODS OF USE THEREOF

Номер: US20150118187A1
Принадлежит: MEDGENICS MEDICAL ISRAEL LTD.

The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a nucleic acid sequence operably linked to one or more regulatory sequences. The present invention is further directed to methods providing sustained expression of therapeutic polypeptides and prolonged therapeutic effects, such as erythropoietin and interferon.

Подробнее
28-02-2023 дата публикации

Particle-drop structures and methods for making and using the same

Номер: US0011590489B2
Автор: Dino Di Carlo, Chueh-Yu Wu

Sub-millimeter scale three-dimensional (3D) structures are disclosed with customizable chemical properties and/or functionality. The 3D structures are referred to as drop-carrier particles. The drop-carrier particles allow the selective association of one solution (i.e., a dispersed phased) with an interior portion of each of the drop-carrier particles, while a second non-miscible solution (i.e., a continuous phase) associates with an exterior portion of each of the drop-carrier particles due to the specific chemical and/or physical properties of the interior and exterior regions of the drop-carrier particles. The combined drop-carrier particle with the dispersed phase contained therein is referred to as a particle-drop. The selective association results in compartmentalization of the dispersed phase solution into sub-microliter-sized volumes contained in the drop-carrier particles. The compartmentalized volumes can be used for single-molecule assays as well as single-cell, and other single-entity ...

Подробнее
22-03-2023 дата публикации

METHODS FOR ISOLATING GAMMA DELTA T CELLS

Номер: EP4150055A1
Принадлежит:

Подробнее
01-03-2018 дата публикации

СПОСОБ ПОЛУЧЕНИЯ ИНДУЦИРОВАННЫХ НЕРВНЫХ СТВОЛОВЫХ КЛЕТОК, ПЕРЕПРОГРАММИРОВАННЫХ ИЗ КЛЕТОК, НЕ ЯВЛЯЮЩИХСЯ НЕРВНЫМИ, С ИСПОЛЬЗОВАНИЕМ HMGA2

Номер: RU2646099C2

Изобретение относится к области клеточной биологии, конкретно к получению индуцированной нервной стволовой клетки из дифференцированной клетки. Способ включает доставку в клетку, не являющуюся нервной, набора для индукции перепрограммирования, состоящего из белка SOX2 или молекулы нуклеиновой кислоты, кодирующей белок SOX2, и белка HMGA2 или молекулы нуклеиновой кислоты, кодирующей белок HMGA2, либо увеличение экспрессии указанных белков в клетке с последующим культивированием. Изобретение позволяет производить скрининг стимулятора или ингибитора регенерации, индивидуально подобранного для пациента терапевтического средства, а также способ лечения и профилактики заболеваний, обусловленных повреждением нервных стволовых клеток. 7 н. и 12 з.п. ф-лы, 31 ил., 21 пр.

Подробнее
04-03-2024 дата публикации

КУЛЬТУРАЛЬНАЯ СРЕДА ДЛЯ ЭПИТЕЛИАЛЬНЫХ КЛЕТОК РАКА ГОРТАНИ, СПОСОБ КУЛЬТИВИРОВАНИЯ И ИХ ПРИМЕНЕНИЕ

Номер: RU2814719C1

Настоящее изобретение относится к области биотехнологии. Изобретение раскрывает новую культуральную среду, содержащую ингибитор киназы MST1/2 и обеспечивающую более короткий период культивирования клеток в сравнении с известными аналогами. Изобретение может быть применимо для культивирования или размножения in vitro эпителиальных клеток первичного рака гортани. Клеточная модель, полученная с применением культуральной среды для первичных клеток согласно настоящему изобретению, может быть использована для оценки эффективности и скрининга лекарственных средств, подходящих для лечения рака гортани. 3 н. и 8 з.п. ф-лы, 10 ил., 6 табл., 7 пр.

Подробнее
10-10-2013 дата публикации

Cell suspension and use thereof

Номер: AU2013202587A1
Принадлежит:

PCT Patent Application Attorney Docket No. 127630-010501/PCT The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration.

Подробнее
05-11-2015 дата публикации

Method for producing reprogrammed derivative neuronal stem cell from non-neuronal cell by using HMGA2

Номер: AU2014250190A1
Принадлежит:

The present invention relates to a method for producing a reprogrammed derivative neuronal stem cell from a differentiated cell. A method for producing a derivative neuronal stem cell according to the present invention can produce a derivative neuronal stem cell from a non-neuronal cell only by using two derivative factors of SOX2 and HMGA2, and so is more effective compared to the conventional method using 4 derivative factors or 5 derivative factors. Also the method considerably enhances the derivation efficiency and proliferation capability compared to the method using only one derivative fact of SOX2, thus enlarging the applicability of the stem cell to treating diseases.

Подробнее
01-10-2020 дата публикации

HIGHLY FUNCTIONAL MANUFACTURED STEM CELLS

Номер: CA3135436A1
Принадлежит:

Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5- positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof.

Подробнее
26-10-2017 дата публикации

ENGINEERED SKIN EQUIVALENT, METHOD OF MANUFACTURE THEREOF AND PRODUCTS DERIVED THEREFROM

Номер: CA0003021688A1
Принадлежит:

Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same.

Подробнее
09-06-2016 дата публикации

METHODS FOR DEVELOPMENT AND USE OF MINIMALLY POLARIZED FUNCTION CELL MICRO-AGGREGATE UNITS IN TISSUE APPLICATIONS USING LGR4, LGR5 AND LGR6 EXPRESSING EPITHELIAL STEM CELLS

Номер: CA0002969707A1
Принадлежит:

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.

Подробнее
14-01-2020 дата публикации

METHOD FOR PREPARING INDUCED PARAXIAL MESODERM PROGENITOR (IPAM) CELLS AND THEIR USE

Номер: CA0002847325C

The present invention relates to an ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells, said method comprising the step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of the Wnt signaling pathway and an effective amount of an inhibitor of the Bone Morphogenetic Protein (BMP) signaling pathway.

Подробнее
07-03-2013 дата публикации

METHOD FOR PREPARING INDUCED PARAXIAL MESODERM PROGENITOR (IPAM) CELLS AND THEIR USE

Номер: CA0002847325A1
Принадлежит:

The present invention relates to an ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells, said method comprising the step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of the Wnt signaling pathway and an effective amount of an inhibitor of the Bone Morphogenetic Protein (BMP) signaling pathway.

Подробнее
18-12-2014 дата публикации

SERUM-FREE MEDIUM CONTAINING PDGF FOR DS CELLS

Номер: CA0002917684A1
Принадлежит:

Provided is a serum-free medium that is suitable for culturing DS cells. The serum-free medium for culturing dermal sheath (DS) cells, said serum-free medium containing platelet-derived growth factor (PDGF), or a method for culturing DS cells using the serum-free medium that contains PDGF.

Подробнее
24-09-2009 дата публикации

COMBINED CHEMICAL AND GENETIC APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS

Номер: CA0002718904A1
Принадлежит:

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Подробнее
04-12-2018 дата публикации

METTL3 gene knockout cell line, construction method thereof and interference vector

Номер: CN0108929863A
Принадлежит:

Подробнее
21-12-2018 дата публикации

Method for constructing skin tissue

Номер: CN0109055303A
Принадлежит:

Подробнее
05-12-2018 дата публикации

METHOD FOR TESTING SKIN IRRITATION USING CULTURED SKIN

Номер: KR1020180129177A
Принадлежит:

The present invention relates to a method for testing a skin irritation, and more specifically, to a method for testing a skin irritation using cultured skin. The method for testing a skin irritation according to the present invention uses cultured skin obtained by changing a manufacturing condition, and thus can have improved estimating power through the reference suitability of accuracy. COPYRIGHT KIPO 2019 ...

Подробнее
13-12-2007 дата публикации

ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS

Номер: WO2007143139A1
Автор: FRANK, Markus, H.
Принадлежит:

The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P- glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.

Подробнее
26-08-2020 дата публикации

СПОСОБ ПРОИЗВОДСТВА КУЛЬТИВИРУЕМЫХ КЛЕТОК И ЛЕКАРСТВЕННОГО ПРЕПАРАТА ДЛЯ ЛЕЧЕНИЯ СПИННОМОЗГОВЫХ ТРАВМ

Номер: RU2730864C1

Изобретение относится к области биотехнологии, а именно к получению культивированных клеток для лечения спинномозговых травм и изготовлению лекарственного средства для лечения спинномозговых травм. Способ включает этап культивирования нейральных клеток-предшественников, полученных из биоптатов кожи человека, в бессывороточной питательной среде, содержащей химическое соединение SAG, при этом полученные указанным способом клетки включают мРНК нейротрофического фактора глиальной клеточной линии (GDNF) и белок CD73. Лекарственное средство содержит, по меньшей мере, культивированные нейральные клетки- предшественники, среду, полученную на предыдущем этапе, и продукт секреции, полученный на предыдущем этапе. Изобретение позволяет расширить арсенал технических средств. 2 н. и 6 з.п. ф-лы, 6 ил., 8 пр.

Подробнее
20-09-2012 дата публикации

Ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders

Номер: AU2011225222A1
Принадлежит:

The purpose of the present invention is to provide a medicament which is useful for amelioration or treatment of chronic prostatitis, interstitial cystitis and/or urination disorders. Specifically, the present invention relates to a novel pharmaceutical use of an extract from inflamed tissue inoculated with vaccinia virus, and relates to an ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders, said agent containing the extract as an active ingredient. The medicament of the present invention containing the extract as an active ingredient is extremely useful as a highly effective and highly safe ameliorating or therapeutic agent for chronic prostatitis, interstitial cystitis and/or urination disorders.

Подробнее
20-02-2020 дата публикации

Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using LGR4, LGR5 and LGR6 expressing epithelial stem cells

Номер: AU2015355187C1
Принадлежит: Davies Collison Cave Pty Ltd

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.

Подробнее
06-02-2020 дата публикации

Stem cell-derived skin precursor cell culture medium and preparation method therefor

Номер: AU2018290634A1
Принадлежит: FB Rice Pty Ltd

Provided are a method for preparing a stem cell-derived skin precursor cell culture medium, comprising the steps of: culturing stem cells in a differentiation medium containing ascorbic acid and hydrocortisone to differentiate the stem cells into stem cell-derived skin precursor cells; culturing the differentiated, stem cell-derived skin precursor cells in a medium to produce a culture of stem cell-derived skin precursor cells; and recovering the stem cell-derived skin precursor cell culture medium from the a culture of the stem cell-derived skin precursor cells, a stem cell-derived skin precursor cell culture medium prepared by the method, and a method for producing a protein from stem cell-derived skin precursor cells, comprising the preparing method.

Подробнее
16-05-2019 дата публикации

METHOD FOR PRODUCING CULTURED CELL, AND METHOD FOR PRODUCING THERAPEUTIC AGENT FOR SPINAL CORD INJURY DISEASE

Номер: CA0003080691A1
Принадлежит: AGENCE DE BREVETS FOURNIER

... [Problem] To provide a cell culture method which can achieve the increase in safe expression of GDNF gene (mRNA) without needing to employ a gene transfer method using a virus. [Solution] A method for producing a cultured cell containing mRNA for glial cell line derived neurotrophic factor (GDNF), the method including a culture step of culturing a human skin-derived stem cell in a serum-free culture medium containing at least one component selected from SAG, purmorphamine and sonic hedgehog (SHH) protein, wherein the serum-free culture medium may additionally contain a B-27 supplement, a ROCK inhibitor, EGF and FGF2.

Подробнее
07-11-2013 дата публикации

METHODS FOR USING AUTOLOGOUS FIBROBLASTS TO ALTER SKIN IDENTITY

Номер: CA0002871852A1
Принадлежит:

The present invention relates to the field of autologous fibroblasts. More specifically, the present invention provides methods and compositions comprising autologous fibroblasts and uses thereof to alter skin identity. In certain embodiments, volar fibroblasts can be expanded for the ability to induce volar skin at the stump site in amputees. In other embodiments, fibroblasts from haired scalp can be expanded to ameliorate alopecias.

Подробнее
31-08-2018 дата публикации

Skin cell dispersion liquid

Номер: CN0108467849A
Принадлежит:

Подробнее
07-04-2020 дата публикации

Method for preparing reinforced and toughened levo-polylactic acid composite membrane based on wool keratin cortical cells

Номер: CN0109232932B
Автор:
Принадлежит:

Подробнее
24-06-2016 дата публикации

HUMAN SKIN MODEL AND USE THEREOF FOR EVALUATING EX VIVO THE DERMATOLOGICAL EFFECTS, COSMETIC AND/OR NUTRACEUTICAL COMPOUNDS

Номер: FR0003030572A1

L'invention concerne un modèle de peau humaine maintenant ex vivo une intégrité histologique et une fonctionnalité biologique de la peau, comprenant en combinaison un échantillon de peau humaine de dimension comprise entre 5 et 10 mm et constitué d'un épiderme (1) et d'un derme (2) placé sur un support (3) présentant au niveau de sa base poreuse (4) la même dimension que l'échantillon de peau, le derme (2) de l'échantillon de peau et la base du support (4) baignant dans un contenant (6) comprenant un milieu de culture (5) renouvelé tous les un à trois jours. L'invention concerne également l'utilisation du modèle de peau humaine pour évaluer ex vivo des composés ou formulations d'intérêt, un procédé de modélisation et d'analyse d'un traitement sélectionné de la peau humaine et l'utilisation d'un échantillon de peau humaine ex vivo pour analyser un traitement sélectionné de la peau.

Подробнее
29-06-2018 дата публикации

MODEL OF SKIN INCLUDING EPIDERMIS, DERMIS AND HYPODERMIS, ITS PREPARATION PROCESS AND ITS USE

Номер: FR0003061206A1
Принадлежит: LABORATOIRES CLARINS

La présente invention se rapporte à un procédé de préparation de modèle de peau complète de mammifère, au système de culture permettant la mise en œuvre de ce procédé, au modèle de peau complète obtenu par ce procédé et à son utilisation pour le criblage et/ou l'évaluation d'actifs et d'excipients cosmétiques.

Подробнее
01-11-2016 дата публикации

ADULT STEM CELL DERIVED FROM HUMAN SKIN TISSUE OF HUMAN AND CELLULAR THERAPEUTIC AGENT COMPRISING SAME

Номер: KR1020160125759A
Принадлежит:

The present invention relates to an adult stem cell derived from the human skin tissue and a cellular therapeutic agent comprising the same. The stem cell of the present invention having excellent proliferation is maintained in an undifferentiated state for a long period of time, and can be differentiated into various types of cells such as osteoblastic cells, chondrogenesis cells, fat cells, liver cells, and the like. Accordingly, the stem cell can be efficiently used in related fields as a cellular therapeutic agent comprising the stem cell. A culture method of a stem cell performs the explant culture of the adult stem cell derived from the human skin tissue. COPYRIGHT KIPO 2016 ...

Подробнее
10-05-2018 дата публикации

THREE-DIMENSIONAL CELL CULTURE SYSTEM COMPRISING PEG-BASED HYDROGEL

Номер: KR1020180047433A
Принадлежит:

The present invention relates to a three-dimensional cell culture system comprising polyethylene glycol (PEG)-based hydrogel. The PEG-based hydrogel is prepared by mixing polyethylene glycol-vinylsulfone (PEG-VS), which is PEG bound to vinylsulfone, adhesion peptide, and a crosslinker. The system can culture dermal fibroblast, melanocytes, or keratin cells, which are skin cells, and thus can be advantageously used to measure the activity of skin cells. COPYRIGHT KIPO 2018 (AA) Three-dimensional PEG-based hydrogel based non-cellular niche mimicking a micro-environment of dermal tissue in skin (BB) Develop a three dimensional culturing system of dermatophyte capable of making dermal tissue in a three dimensional shape (CC) Induce human dermatophyte to be generated (DD) Simulation diagram of vinyl sulfone (VS)-functionalized PEG- based hydrogel (EE) Simulation diagram of three-dimensional scaffold PEG-hydrogel ...

Подробнее
31-10-2018 дата публикации

Номер: KR1020180118795A
Автор:
Принадлежит:

Подробнее
14-09-2021 дата публикации

Polypeptides and antibodies to treat skin conditions associated with overproduction of sebum

Номер: US0011117939B2

The present application provides compositions, methods, and uses of polypeptide or antibody inhibitors of insig-1 ubiquitination for preventing or treating skin diseases or conditions associated with overproduction of sebum, such as acne and seborrhea.

Подробнее
26-03-2020 дата публикации

CELL SUSPENSION AND USE THEREOF

Номер: US20200093952A1
Принадлежит:

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration. 149-. (canceled)50. A method for treating a chronic wound in skin of a patient , comprising:preparing an autologous cell suspension without in vitro culturing; andadministering the cell suspension to the chronic wound of the patient to promote tissue regeneration at the chronic wound.51. The method of claim 50 , wherein the chronic wound is a chronic ulcer.52. The method of claim 51 , wherein the chronic ulcer is a diabetic ulcer.53. The method of claim 51 , wherein the chronic ulcer is at least one selected from the group consisting of a venous ulcer claim 51 , an arterial ulcer claim 51 , and a mixed arterio-venous ulcer.54. The method of claim 50 , wherein the chronic wound is at least one selected from the group consisting of a neuropathic ulcer and a pressure sore.55. The method of claim 50 , wherein preparing the autologous cell suspension comprises obtaining a skin tissue sample from the patient claim 50 , collecting a population of cells from the skin tissue sample claim 50 , and mixing the population of cells with a nutrient solution to create the autologous ...

Подробнее
10-04-2012 дата публикации

Pluripotent cells from the mammalian late epiblast layer

Номер: US0008153423B2
Принадлежит: PEDERSEN ROGER, VALLIER LUDOVIC, BRONS GABRIELLE

This invention relates to the isolation and propagation of pluripotent cells isolated from the mammalian late epiblast layer, termed Epiblast Stem Cells' (EpiSCs). These cells are useful in a range of applications, including the generation of transgenic animal species.

Подробнее
10-02-2022 дата публикации

COMPOSITION COMPRISING INDUCED EXOSOME FOR HAIR REGENERATION

Номер: US20220040238A1
Автор: Yong Seung LEE
Принадлежит:

A method for producing exosomes comprises steps of: providing ultrasound stimulation directly or indirectly to cells; culturing a mixture of the cells and a medium for a predetermined time; and isolating exosomes from the mixture, wherein providing the stimulation directly to the cells comprises applying ultrasound stimulation to the medium containing the cells, and the providing the stimulation indirectly to the cells comprises applying ultrasound stimulation to the medium not containing the cells and then mixing the medium and the cells. This method for producing exosomes makes it possible to obtain exosomes having a hair regeneration effect not only from stem cells and progenitor cells that are difficult to isolate and multiply, but also from somatic cells that may be easily obtained and maintained, in high yield within a short time by ultrasound treatment that is a simple process. 1. A method for producing exosomes having a hair regeneration effect , the method comprising steps of:providing ultrasound stimulation directly or indirectly to cells;culturing a mixture of the cells and a medium for a predetermined time; andisolating exosomes from the mixture,wherein the providing the stimulation directly to the cells is applying ultrasound stimulation to a medium containing the cells, andthe providing the stimulation indirectly to the cells is applying ultrasound stimulation to a medium not containing the cells and then mixing the medium and the cells.2. The method of claim 1 , wherein the step of providing ultrasound stimulation directly or indirectly to cells is performed by any one method selected from among:a method of mixing the cells and a medium and then providing ultrasound stimulation to the mixture; ora method of providing ultrasound stimulation to a medium and then mixing the medium and the cells; ora method of providing ultrasound stimulation to the cells and then mixing the cells and a medium; ora method of providing ultrasound stimulation to the cells ...

Подробнее
22-07-2010 дата публикации

HUMAN EMBRYONIC STEM CELL DERIVED MESODERM-LIKE EPITHELIUM TRANSITIONS TO MESENCHYMAL PROGENITOR CELLS

Номер: US20100184212A1
Принадлежит:

Human embryonic stem cells (hESC) have the potential to produce all of the cells in the body. They are also able to self-renew indefinitely, sparking the hope they could be used as a source for large scale production of therapeutic cell lines. The present invention relates to a monolayer differentiation culture system that induces hESC (WA09 and BG01) to form epithelial sheets with mesodermal gene expression patterns (BMP4, RUNX1, GAT A4). These E-cadherin+ CD90lovv cells then undergo apparent epithelial-mesenchymal transformation (EMT) for the derivation of mesenchymal progenitor cells (hES-MC) that by flow cytometry are negative for hematopoietic (CD34, CD45 and CD 133) and endothelial (CD31 and CD 146) markers, but positive for markers associated with mesenchymal stem cells (MSC) (CD73, CD90, CD105 and CD166). To determine their functionality, we tested their capacity to produce the three lineages commonly associated with MSC and found they could form osteogenic and chondrogenic, but ...

Подробнее
13-09-2012 дата публикации

Conditioned cell culture medium compositions and methods of use

Номер: US20120230940A1
Принадлежит: Skinmedica Inc

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

Подробнее
21-03-2013 дата публикации

6,8-DISUBSTITUTED PURINE COMPOSITIONS

Номер: US20130072506A1
Принадлежит:

6,8-Disubstituted purines which can be used in drug and cosmetic compositions and/or applications are provided. These 6,8-disubstituted purines have a wide range of biological activities, including for example anti-inflammatory, anti-senescent, as well as well as other activities which are especially useful in pharmaceutical and cosmetic applications. The 6,8-disubstituted purine compounds and compositions containing such 6,8-disubstituted purines provide growth-regulatory, differentiating, antisenescent and antiaging properties with improved selectivities and efficiencies and lower toxicities than analogues known heretofore. 2. The 6 claim 1 ,8-disubstituted purines of claim 1 , wherein Ris selected from the group consisting of furfuryl claim 1 , phenyl claim 1 , benzyl claim 1 , 3-methylbut-2-en-1-yl claim 1 , cyclohexylmethyl claim 1 , allyl claim 1 , and 3 claim 1 ,3-dimethylallyl claim 1 , wherein the selected Rcan be unsubstituted or substituted with one or more halogen claim 1 , hydroxy claim 1 , methoxy claim 1 , methyl claim 1 , amino claim 1 , nitro or combinations thereof.3. The 6 claim 1 ,8-disubstituted purines of claim 1 , wherein R8 is selected from the group consisting of amino claim 1 , hydroxy claim 1 , chloro claim 1 , fluoro claim 1 , bromo claim 1 , amino(C-Calkyl)amino claim 1 , hydroxy(C-Calkyl)amino claim 1 , NHOH claim 1 , NHNH claim 1 , carboxyl claim 1 , nitro claim 1 , sulphanyl claim 1 , methylsulphanyl claim 1 , and methoxy.4. The 6 claim 3 ,8-disubstituted purines of claim 3 , wherein R8 is amino.5. The 6 claim 1 ,8-disubstituted purines of claim 1 , wherein the 6 claim 1 ,8-disubstituted purines are 6-furfurylamino-8-(amino claim 1 , hydroxy claim 1 , chloro claim 1 , fluoro claim 1 , bromo claim 1 , amino(C-Calkyl)amino claim 1 , hydroxy(C-Calkyl)amino claim 1 , NHOH claim 1 , NHNH claim 1 , carboxyl claim 1 , nitro claim 1 , sulphanyl claim 1 , methylsulphanyl claim 1 , methoxy)purine claim 1 , 6-(3-hydroxybenzylamino)-8-(amino ...

Подробнее
25-04-2013 дата публикации

Method for preparing dermis tissue cells aggregation and uses thereof

Номер: US20130101564A1
Автор: Jinxi Chen
Принадлежит: Individual

Dermis tissue cell aggregation, which comprises isolated dermis tissue cells with biological activity, is provided. The isolated dermis tissue cells are preserved in a mixed solution consisting of an isotonic saline solution for medical use, an anticoagulant, a nutrient for cells and a cell growth promoter, and a non-fluidity dermis tissue cell aggregation with adhesion is formed after several processes. A method for preparing the dermis tissue cell aggregation and the use thereof in preparing medicines for repairing scars are provided.

Подробнее
15-08-2013 дата публикации

Bioactive amino acid sequence and use therefrom

Номер: US20130210147A1
Принадлежит: SOLVAY SA

Use of the amino acid sequence Har-Gly-Asp (hRGD) as a bioactive sequence in functional peptides to promote cell adhesion, cell growth, and/or cell differentiation, and in the preparation of hydrogels, preferably hydrogels for cell culture. A hydrogel comprising the hRGD sequence, especially a hydrogel wherein the hRGD sequence is part of the hydrogel scaffold. 1. A method for promoting cell adhesion , cell growth , cell differentiation , or combinations thereof , comprising using an amino acid sequence Har-Gly-Asp (hRGD) as a bioactive sequence in a functional peptide moiety.2. The method according to claim 1 , wherein the functional moiety comprises at least one sequence selected from the group consisting of GhRGD claim 1 , YhRGD claim 1 , YGhRGD claim 1 , GGGGhRGD claim 1 , βAla-hRGD claim 1 , GABA-hRGD claim 1 , 6-aminovalericamide-hRGD claim 1 , hRGDS claim 1 , hRGDY claim 1 , hRGDF claim 1 , hRGDK claim 1 , hRGDV claim 1 , hRGDT claim 1 , hRGDWP claim 1 , hRGDFK claim 1 , hRGDYK claim 1 , hRGDSP claim 1 , hRGDSPK claim 1 , hRGDSY claim 1 , hRGDNP claim 1 , hRGDTP claim 1 , hRGDSP claim 1 , GhRGDS claim 1 , GhRGDY claim 1 , GhRGDF claim 1 , GhRGDSY claim 1 , GhRGDSP claim 1 , GhRGDSPK claim 1 , YhRGDS claim 1 , GhRGDTP claim 1 , GhRGDSPK claim 1 , GhRGDSP claim 1 , GhRGDK claim 1 , GGGGhRGDS claim 1 , GhRGDNP claim 1 , and combinations thereof.3. The method according to claim 1 , wherein the functional peptide moiety is covalently bound to a self-assembling peptide moiety.4. The method according to claim 3 , wherein the self-assembling peptide moiety is able to self-assemble in a β-sheet claim 3 , a coiled coil α-helix structure claim 3 , or a peptide triple helix structure.5. The method according to claim 1 , wherein the functional peptide moiety is covalently bound to a biocompatible polymer.6. The method according to claim 5 , wherein the functional peptide moiety is bound to the biocompatible polymer through a linkage selected from the group consisting of a ...

Подробнее
05-09-2013 дата публикации

Cellular Preparations For Wound Management

Номер: US20130230494A1
Автор: Simon Marcia

Disclosed herein are methods of preserving or preparing cell-based compositions for use in wound management. The methods can be carried out by steps including: (a) providing skin cells; (b) treating the skin cells with a monosaccharide; (c) treating the skin cells with a disaccharide; and (d) lyophilizing the skin cells. 1. A method of preserving or preparing cell-based compositions for use , the method comprising:(a) providing skin cells;(b) treating the skin cells with a monosaccharide;(c) treating the skin cells with a disaccharide; and(d) lyophilizing the skin cells.2. The method of claim 1 , wherein the skin cells are epidermal cells claim 1 , dermal cells claim 1 , or a combination of epidermal and dermal cells.3. The method of claim 1 , wherein the skin cells are fibroblasts claim 1 , keratinocytes claim 1 , Langerhans cells claim 1 , melanocytes claim 1 , Merkel cells claim 1 , melanocytes claim 1 , or a combination thereof.4. (canceled)5. The method of claim 1 , wherein treating the cells with a monosaccharide comprises exposing the cells to a solution comprising glucose at about 0.5-2.0 M.6. The method of claim 5 , wherein the solution comprises glucose at about 1.7 M.7. The method of claim 1 , wherein treating the cells with a disaccharide comprises exposing the cells to a solution comprising trehalose at about 0.1-0.5 M.8. The method of claim 7 , wherein the solution comprises trehalose at about 0.23 M.9. The method of claim 1 , further comprising treating the cells with a poloxamer and/or serum albumin.10. The method of claim 9 , wherein the poloxamer and/or the serum albumin is present in a solution comprising the monosaccharide and/or a solution comprising the disaccharide.11. (canceled)12. The method of claim 1 , further comprising formulating the cells as a dry powder claim 1 , suspension claim 1 , solution claim 1 , gel claim 1 , cream claim 1 , ointment claim 1 , or biocompatible matrix claim 1 , optionally further comprising a physiologically ...

Подробнее
14-11-2013 дата публикации

Pluripotent cells from mammalian late epiblast layer

Номер: US20130302846A1
Принадлежит:

The invention relates to the isolation and propagation of pluripotent cells isolated from the mammalian late epiblast layer, termed Epiblast Stem Cells (EpiSCs). These cells are useful in a range of applications, including the generation of transgenic animal species. 138.-. (canceled)39. A method of differentiating mouse or rat Epiblast Stem Cells (EpiSCs) into progenitor cells of an ectoderm lineage comprising culturing the mouse or rat EpiSCs in a chemically defined medium (CDM) supplemented with FGF2 and an activin antagonist such that the mouse or rat EpiSCs differentiate into progenitor cells of an ectoderm lineage.40. The method of wherein the activin antagonist is selected from the group consisting of SB431542 claim 39 , Lefty claim 39 , Cerberus and follistatin.41. The method of wherein the progenitor cells of an ectoderm lineage are partially differentiated cells.42. The method of wherein the progenitor cells of an ectoderm lineage are fully differentiated cells.43. The method of wherein the fully differentiated cells are selected from the group consisting of neurons claim 42 , astrocytes and oligodendrocytes.44. The use of the progenitor cells of an ectoderm lineage of in a drug screening application claim 39 , in an in vitro modeling application claim 39 , or in transplantation.45. A method of differentiating mouse or rat EpiSCs into progenitor cells of a mesoderm lineage comprising culturing the mouse or rat EpiSCs in a CDM supplemented with Activin claim 39 , FGF2 and BMP4 such that the mouse or rat EpiSCs differentiate into progenitor cells of a mesoderm lineage.46. The method of wherein the progenitor cells of a mesoderm lineage are partially differentiated cells.47. The method of wherein the progenitor cells of a mesoderm lineage are fully differentiated cells.48. The use of the progenitor cells progenitor cells of a mesoderm lineage of in a drug screening application claim 45 , in an in vitro modeling application claim 45 , or in transplantation.49. ...

Подробнее
21-11-2013 дата публикации

Immortalization of Epithelial Cells and Methods of Use

Номер: US20130309681A1
Принадлежит: GEORGETOWN UNIVERSITY

The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing. 158-. (canceled)59. A method of continuously culturing non-keratinocyte epithelial cells , the method comprisinga) culturing the non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium, andb) inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing.60. The method of claim 59 , wherein the non-keratinocyte epithelial cells are selected from the group consisting of squamous cells claim 59 , columnar cells claim 59 , adenomatous cells and transitional epithelial cells.61. The method of claim 60 , wherein the non-keratinocyte epithelial cells are selected from the group consisting of prostate cells claim 60 , mammary cells claim 60 , hepatocytes claim 60 , pancreatic islet cells claim 60 , pulmonary epithelial cells claim 60 , kidney cells claim 60 , bladder cells claim 60 , stomach epithelial cells claim 60 , large intestinal epithelial cells claim 60 , small intestinal epithelial cells claim 60 , urethral epithelial cells claim 60 , testicular epithelial cells claim 60 , ovarian epithelial cells claim 60 , thyroid cells claim 60 , parathyroid cells claim 60 , adrenal cells claim 60 , thymus cells claim 60 , gall bladder cells and pituitary cells.62. The method of claim 59 , wherein the calcium-containing medium comprises serum or a serum replacement.63. The method of claim 59 , wherein the feeder cells are proliferating or non-proliferating fibroblasts.64. The method of claim 59 , wherein inhibiting the activity of ROCK comprises culturing the non-keratinocyte epithelial cells in the presence of ...

Подробнее
28-11-2013 дата публикации

ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS

Номер: US20130315880A1
Автор: Frank Markus H.
Принадлежит: CHILDREN'S MEDICAL CENTER CORPORATION

The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. 1. A method for inducing tissue generation , comprising promoting differentiation of an isolated preparation of ABCB5 positive dermal mesenchymal stem cells , wherein ABCB5 positive dermal cells comprise at least 95% of the isolated preparation of ABCB5 positive dermal mesenchymal stem cells.2. The method of claim 1 , wherein the isolated preparation of ABCB5 positive dermal mesenchymal stem cells are first grown in an undifferentiated state through mitotic expansion.3. The method of claim 1 , wherein the isolated preparation of ABCB5 positive dermal mesenchymal stem cells are harvested and activated to differentiate into bone claim 1 , cartilage claim 1 , ligament claim 1 , tendon claim 1 , stroma claim 1 , muscle and adipose tissue.4. The method of claim 1 , wherein the isolated preparation of ABCB5 positive dermal mesenchymal stem cells are seeded onto a matrix or scaffold.5. The method of claim 4 , wherein the matrix is a polymeric mesh or sponge.6. The method of claim 4 , wherein the matrix is a polymeric hydrogel.7. The method of claim 1 , wherein the ABCB5 positive dermal mesenchymal stem cells are injected into a soft or hard tissue defect.8. The method of claim 7 , wherein the tissue defect is a trauma or burn.9. A matrix seeded with a population of dermal stem cells claim 7 , wherein at least 95% of the population of dermal stem cells are ABCB5+ dermal mesenchymal stem cells.10. The matrix of claim 9 , wherein the matrix is shaped to fill a tissue defect.11. The matrix of claim 9 , ...

Подробнее
07-01-2021 дата публикации

Method for Assessing a Compound Interacting with a Target on Epithelial Cells

Номер: US20210003559A1

Disclosed herein is a method for assessing a compound interacting with a target on polarized epithelial cells. The method comprising the steps of providing an organ chip comprising a main channel and polarized epithelial cells, wherein the main channel is divided into an apical channel and a basal channel separated by the polarized epithelial cells, wherein the apical side of the polarized epithelial cells is directed towards the apical channel and the basolateral side of the polarized epithelial cells is directed towards the basal channel. Determining the localization and optionally the expression level of the target on the polarized epithelial cells. Administering the compound and optionally immune cells, preferably peripheral blood mononuclear cells (PBMC) to the basal channel, when the target is localized on the basolateral side of the epithelial cells or administering the compound and optionally immune cells, preferably peripheral blood mononuclear cells (PBMC) to the apical channel, when the target is localized on the apical side of the epithelial cells. Measuring a parameter of the administration of the compound and the peripheral blood mononuclear cells.

Подробнее
27-01-2022 дата публикации

METHOD FOR EXTENDING TELOMERE OF CELL

Номер: US20220025352A1
Автор: LEE Yong Seung
Принадлежит:

A method for elongating telomeres of cells comprises steps of: providing physical stimulation directly or indirectly to cells; and culturing a mixture of the cells and a medium for a predetermined time, wherein providing the stimulation directly to the cells comprises applying physical stimulation to the medium containing the cells, and providing the stimulation indirectly to the cells comprises applying physical stimulation to the medium not containing the cells and then mixing the medium and the cells. The method for elongating telomeres of cells is simpler than a conventional method and is superior in terms of time, cost, efficiency, and safety. In addition, the method induces cell division and provides an anti-aging effect, in addition to simply elongating telomeres. Thereby, it is expected that the method can ameliorate and prevent not only problems caused by shortening of telomeres, but also various aging-related diseases and conditions. 1. A method for elongating telomeres of cells , the method comprising steps of:providing physical stimulation directly or indirectly to the cells; andculturing a mixture of the cells and a medium for a predetermined time,wherein the providing the stimulation directly to the cells is applying the physical stimulation to a medium containing the cells, and the providing the stimulation indirectly to the cells is applying the physical stimulation to the medium not containing a cells and then mixing the medium and the cells.2. The method of claim 1 , wherein a form of the physical stimulation is any one selected from among ultrasound claim 1 , heat claim 1 , and light.3. The method of claim 1 , wherein the step of providing the physical stimulation directly or indirectly to the cells is performed by any one method selected from among:a method of mixing the cells and the medium and then providing the physical stimulation to the mixture; ora method of providing the physical stimulation to a medium and then mixing the medium and the ...

Подробнее
17-04-2014 дата публикации

CELL MASS CAPABLE OF SERVING AS A PRIMITIVE ORGAN-LIKE STRUCTURE COMPRISED OF A PLURALITY OF CELL TYPES OF SOMATIC ORIGIN

Номер: US20140106432A1
Принадлежит: SHISEIDO COMPANY, LTD.

The present invention provides a method of producing a cell mass capable of serving as a primitive organ-like structure comprised of a plurality of somatic cell types of somatic origin, comprising: preparing cultures containing the plurality of types of somatic cells; mixing the plurality of types of somatic cell cultures followed by adding a Wnt signal activator to the mixed cell culture; subjecting the culture containing the Wnt signal activator to non-plate contact culturing over a predetermined time period; and replacing the medium of the culture cultured by the non-plate contact culturing with medium not containing Wnt signal activator and further culturing for a predetermined time period; wherein, at least one type of the plurality of somatic cells is maintained in an undifferentiated state. 114-. (canceled)15. A method of producing a cell mass capable of serving as a primitive organ-like structure comprised of combinations of outer root sheath (ORS) cells and mesenchymal somatic cells , comprising:preparing cultures containing ORS cells and mesenchymal somatic cells;mixing said ORS cells and mesenchymal somatic cells cultures to obtain a mixed cell culture;adding a Wnt signal activator to the mixed cell culture, wherein the Wnt signal activator inhibits glycogen synthase-kinase-3 (GSK-3) activity;culturing the mixed cell culture containing the Wnt signal activator in no-contact culture plates by hanging drop method or spheroid formation method over a predetermined time period; andreplacing the medium of the culture cultured by the hanging drop method or spheroid formation method with medium not containing Wnt signal activator and further culturing for a predetermined time period;wherein, at least one type of the ORS cells and mesencymal somatic cells is maintained in an undifferentiated state.16. The method according to claim 15 , wherein hair follicles having a hair follicle inducing function are formed from the cell mass.17. The method according to claim 15 ...

Подробнее
10-02-2022 дата публикации

Hair Follicle Germs, Method for Producing Hair Follicle Germs, and Method for Activating Cells Included in Hair Follicle Germs

Номер: US20220041983A1

Provided are a hair follicle germ having excellent hair growth-related properties, a method of producing a hair follicle germ, and a method of activating cells contained in a hair follicle germ. The hair follicle germ includes: epithelial cells; mesenchymal cells; and mesenchymal stem cells. The method of producing a hair follicle germ includes co-culturing epithelial cells, mesenchymal cells, and mesenchymal stem cells to form a hair follicle germ.

Подробнее
16-02-2017 дата публикации

METHOD OF PRODUCING SKIN-DERIVED PRECURSOR CELLS

Номер: US20170044495A1
Автор: NAKAGIRI Yoriko
Принадлежит: KAO CORPORATION

A method of producing skin-derived precursor cells, comprising culturing human-derived pluripotent stem cells in a differentiation-inducing medium containing an agonist of Wnt signaling to differentiate the pluripotent stem cells into skin-derived precursor cells; a differentiation-inducing medium for differentiating human-derived pluripotent stem cells into skin-derived precursor cells, comprising an agonist of Wnt signaling as a differentiation-inducing promoter; and a differentiation-inducing promoter for differentiating human-derived pluripotent stem cells into skin-derived precursor cells, comprising an agonist of Wnt signaling as an active ingredient. 18-. (canceled)9: A method of producing skin-derived precursor cells , comprising:culturing human-derived pluripotent stem cells in a differentiation-inducing medium comprising an agonist of Wnt signaling to differentiate the pluripotent stem cells into skin-derived precursor cells,wherein a basal medium of the differentiation-inducing medium is a D-MEM/Ham's F12 medium, andwherein the differentiation-inducing medium further comprises a B-27 supplement, and at least one nutritional factor selected from the group consisting of epidermal growth factor and basic fibroblast growth factor.10: The method according to claim 9 , wherein the pluripotent stem cells are induced pluripotent stem cells.11: The method according to claim 9 , wherein the pluripotent stem cells are neural crest stem cells derived from pluripotent stem cells.12: The method according to claim 9 , wherein skin-derived precursor cells differentiated using the differentiation-inducing medium are passage-cultured one or more times.13: A method of producing skin-derived precursor cells claim 9 , comprisingculturing human-derived neural crest stem cells in a differentiation-inducing medium comprising an agonist of Wnt signaling to differentiate the neural crest stem cells into skin-derived precursor cells.14: The method according to claim 13 , wherein a ...

Подробнее
03-03-2022 дата публикации

ENGINEERED SKIN EQUIVALENT, METHOD OF MANUFACTURE THEREOF AND PRODUCTS DERIVED THEREFROM

Номер: US20220064451A1
Принадлежит:

Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same.

Подробнее
14-02-2019 дата публикации

METHODS FOR DEVELOPMENT AND USE OF MINIMALLY POLARIZED FUNCTION CELL MICRO-AGGREGATE UNITS IN TISSUE APPLICATIONS USING LGR4, LGR5 AND LGR6 EXPRESSING EPITHELIAL STEM CELLS

Номер: US20190046691A1
Автор: Lough Denver
Принадлежит: PolarityTE, Inc.

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application. 1. A method of producing a composition , comprising:a) separating fat and hypodermal elements from dermal and epidermal compartments of a mammalian tissue specimen to provide a partially processed mammalian tissue specimen; andb) separating remaining cutaneous elements of the partially processed tissue specimen, to provide the composition, wherein the composition comprises a micro-aggregate comprising at least a portion of a follicular bulge and LGR-expressing stem cells, andwherein the composition is capable of assembling functional tissue.2. The method of claim 1 , further comprising adding the composition to a delivery substrate.3. The method of claim 2 , wherein the delivery substrate is selected from scaffolding claim 2 , matrix claim 2 , particle claim 2 , cells claim 2 , fiber claim 2 , or combinations thereof.4. The method of claim 1 , further comprising adding enhancing factors or analytes to the composition.5. The method of claim 2 , further comprising adding enhancing factors or analytes to the composition.6. The method of claim 1 , further comprising applying the composition to a select target.7. The method of claim 2 , further comprising applying the composition to a select target.8. The method of claim 6 , wherein the select target is selected from a tissue region claim 6 , a wound claim 6 , a void claim 6 , a defect tissue claim 6 , or combinations thereof.9. The method claim 7 , wherein the select target is selected from ...

Подробнее
13-02-2020 дата публикации

METHODS AND PRODUCTS FOR TRANSFECTION

Номер: US20200048616A1
Принадлежит:

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed. 19.-. (canceled)10. A method for reprogramming a differentiated cell to a less differentiated state , comprising:(a) providing a differentiated cell;(b) culturing the differentiated cell; and wherein the one or more synthetic RNA molecules include at least one RNA molecule encoding one or more reprogramming factors selected from the group consisting of Oct4 protein, Sox2 protein, Klf4 protein, c-Myc protein, I-Myc protein, Tert protein, Nanog protein, and Lin28 protein;', 'wherein the transfecting results in the cell expressing the one or more reprogramming factors to result in the cell being reprogrammed to a less differentiated state; and', 'wherein step (c) occurs in the presence of a medium containing ingredients that support reprogramming of the differentiated cell to a less differentiated state., '(c) transfecting the differentiated cell with one or more synthetic RNA molecules,'}11. The method of claim 10 , wherein the differentiated cell is derived from a biopsy.12. The method of claim 11 , wherein the differentiated cell is derived from a dermal punch biopsy sample.13. The method of claim 10 , wherein the differentiated cell is from a human subject.14. The method of claim 10 , wherein the differentiated cell is a skin cell.15. The method of claim 10 , further comprising contacting the cell with at least one member of the group: poly-L-lysine claim 10 , poly-L-ornithine claim 10 , RGD peptide claim 10 , fibronectin claim 10 , vitronectin claim 10 , collagen claim 10 , and laminin.16. The method of claim 10 , wherein the one or more synthetic RNA molecules contain at least one of a pseudouridine or a 5-methylcytidine residue.17. The method of claim 10 , wherein ...

Подробнее
28-02-2019 дата публикации

REGENERATED HAIR FOLLICLE PRIMORDIUM AGGREGATION MANUFACTURING METHOD, HAIR FOLLICLE TISSUE-CONTAINING SHEET, AND METHOD FOR MANUFACTURING HAIR FOLLICLE TISSUE-CONTAINING SHEET

Номер: US20190062687A1
Принадлежит:

The present invention provides a method for manufacturing a regular and high-density regenerated hair follicle primordium aggregation similar to the hair follicle tissue of a mammal in a simple manner. A regenerated hair follicle primordium aggregation manufacturing method of the present invention includes a step of forming hair follicle primordia by inoculating a microwell plate, which includes regularly arranged microwell portions, with mesenchymal cells and epithelial cells and culturing a mixture of the cells while supplying oxygen thereto. 1. A regenerated hair follicle primordium aggregation manufacturing method , comprising:a step of inoculating a microwell plate, which has regularly arranged microwell portions, with mesenchymal cells and epithelial cells and culturing a mixture of the cells while supplying oxygen thereto from all surfaces of the microwell plate so as to form hair follicle primordia in the microwell portions,wherein the microwell plate is formed of an oxygen permeable material.2. (canceled)3. A hair follicle tissue-containing sheet , comprising:hair follicle primordia including mesenchymal cells and epithelial cells; anda biocompatible hydrogel,wherein the hair follicle primordia are regularly arranged on the biocompatible hydrogel approximately at the same density as the density of pores of a mammal.4. The hair follicle tissue-containing sheet according to claim 3 , wherein the hair follicle primordia are differentiated and form hair follicles.5. The hair follicle tissue-containing sheet according to claim 3 , wherein the biocompatible hydrogel is an extracellular matrix component which gelates.6. The hair follicle tissue-containing sheet according to claim 5 , wherein the extracellular matrix component is collagen.7. The hair follicle tissue-containing sheet according to claim 3 , wherein the density of the hair follicle primordia is equal to or higher than 20 primordia/cmand equal to or lower than 500 primordia/cm.8. A method for ...

Подробнее
29-05-2014 дата публикации

METHODS FOR FORMING NORMAL REGENERATED TISSUES, THE NORMAL REGENERATED TISSUES AND METHODS FOR ASSESSING SENSITIVITIES AND SO ON

Номер: US20140147831A1
Автор: Shigekazu NAKATSUGAWA

A normal regenerated tissue is formed by exposing to radiation a connective tissue or a supporting tissue originating in an organ to thereby form a feeder layer and then transplanting epithelial cells thereon to form a stratified structure. By conveniently and surely providing regenerated tissue by the 3-dimensional culture with the use of a human-origin normal tissue as a base, it is possible to construct systems for assessing effects and side effects of chemicals such as drugs or assessing sensitivities thereof with the use of regenerated tissues as models of corresponding tissues respectively. 130-. (canceled)31. A normal regenerated tissue comprising a stratified structure of epithelial cells on an irradiated feeder layer from an organ derived fibroblast and vascular endothelial cells , wherein the fibroblasts , the endothelial cells and the epithelial cells arc orthotopic with regard to the originating organ , and wherein the organ is not skin.32. The normal regenerated tissue according to claim 31 , wherein the epithelial cells derive from nerve claim 31 , oral mucosa claim 31 , bronchus claim 31 , mammary gland claim 31 , liver claim 31 , prostate or kidney.33. The normal regenerated tissue according to claim 31 , wherein the feeder layer consisting of a lower layer of the fibroblasts and upper layer of the endothelial cells.34. The normal regenerated tissue according to claim 31 , wherein the epithelial cells are in a stratified structure consisting of four or more layers.35. The normal regenerated tissue according to claim 31 , wherein the normal regenerated tissue is placed on a basal plate.36. The normal regenerated tissue according to claim 31 , wherein a culture medium or culture fluid is allowed to flow in contact with a normal regenerated tissue.37. The normal regenerated tissue wherein a plural of normal regenerated tissue according to are allowed to pass through the channel of the culture medium or culture fluid.38. The normal regenerated tissue ...

Подробнее
24-03-2022 дата публикации

Supplemented Serum-Containing Culture Medium for Enhanced Arpe-19 Growth and Human Cytomegalovirus Vaccine Production

Номер: US20220090005A1
Принадлежит: Merck Sharp & Dohme Corp.

The present invention relates to supplemented serum-containing cell culture media that provides enhances ARPE-19 cell growth and/or improves the yield of human cytomegalovirus (HCMV) grown in ARPE-19 cell cultures. The media of the invention includes two additives, a hormone (e.g., a glucocorticoid hormone such as dexamethasone) and a growth factor (e.g., EGF). The invention further provides methods of producing HCMV in such growth media. 1. A cell culture medium comprising:a basal cell culture medium comprising; a serum comprising between about 0.1 μM and about 10 μM of dexamethasone, and between about 0.1 ng/mL and about 100 ng/mL of epidermal growth factor (EGF).2. The medium of claim 1 , wherein the basal cell culture medium is DMEM/F-12.3. The medium of claim 1 , wherein said serum is fetal bovine serum (FBS).4. The medium of claim 3 , wherein the FBS is present at a concentration between about 2% and about 10% claim 3 , inclusive.5. The medium of claim 1 , wherein the dexamethasone is present at a concentration between about 1 and about 10 μM.6. The medium of claim 1 , wherein the EGF is present at a concentration between about 1 and about 40 ng/mL.7. The medium of claim 1 , further comprising 1× MEM essential amino acids claim 1 , wherein the 1× MEM essential amino acids consist of arginine claim 1 , cysteine claim 1 , histidine claim 1 , isoleucine claim 1 , leucine claim 1 , lysine claim 1 , methionine claim 1 , phenylalanine claim 1 , threonine claim 1 , tryptophan claim 1 , tyrosine claim 1 , and valine.8. The medium of claim 1 , further comprising: 1×-4× glutamine synthetase expression medium (GSEM) supplement claim 1 , wherein the GSEM supplement consists of a mixture of L-alanine claim 1 , L-asparagine claim 1 , L-aspartic acid claim 1 , L-glutamic acid claim 1 , L-proline claim 1 , L-serine claim 1 , adenosine claim 1 , guanosine claim 1 , cytidine claim 1 , uridine claim 1 , and thymidine.9. The medium of claim 1 , further comprising trace elements ...

Подробнее
19-03-2015 дата публикации

Cell Suspension and Use Thereof

Номер: US20150079153A1
Принадлежит: Avita Medical Ltd.

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration. 1. A cell suspension for use in an epithelium-related procedure , comprising:a population of cells including viable and functioning cells derived from an epithelial tissue sample;wherein the population of cells, prior to being used in an epithelium-related procedure, are exposed to a condition selected from the group consisting of stress and an exogenous agent;wherein the population of cells, when used in said epithelium-related procedure and applied to a recipient site, promote treatment, healing, reconstructing, resurfacing, repigmentation and/or regeneration of epithelial tissues.2. The cell suspension of claim 1 , wherein the viable and functioning cells include differentiated cells and cells capable of dividing or differentiating.3. The cell suspension of claim 1 , wherein the epithelial tissue sample is obtained from one or more of skin epithelium claim 1 , respiratory epithelium claim 1 , vascular epithelium claim 1 , corneal epithelium claim 1 , and glandular epithelium.4. The cell suspension of claim 1 , wherein when the epithelial tissue sample is skin tissue ...

Подробнее
23-03-2017 дата публикации

Combined chemical and genetic approaches for generation of induced pluripotent stem cells

Номер: US20170081640A1
Принадлежит: Scripps Research Institute

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Подробнее
29-03-2018 дата публикации

ARTIFICIAL SKIN CULTURE CONTAINER AND METHOD FOR PRODUCING ARTIFICIAL SKIN USING SAME

Номер: US20180087030A1
Принадлежит:

An artificial skin culture container according to the present invention can solve the problems of the contraction of the dermal layer of artificial skin and the detachment thereof from the culture container, which result from an interaction between collagen and fibroblasts existing in the dermal layer of artificial skin during the production of the artificial skin, by using agar and hydrophobically modifying a portion of the agar. Therefore, the use of the culture container enables to stably culture artificial skin and produce artificial skin similar to the human skin. In addition, the artificial skin culture container of the present invention comprises agar, and thus a culture solution can be supplied through a side portion as well as a lower portion of the culture container, which allows to effectively culture artificial skin. 1. An artificial skin culture container , which comprises agar in gel form , wherein a portion of the agar is hydrophobically modified.2. The artificial skin culture container according to claim 1 ,wherein the hydrophobically modified agar is prepared by substituting one or more hydrogen atoms of a agarose in the agar.3. The artificial skin culture container according to claim 2 ,wherein the hydrophobic molecule is selected from the group consisting of:{'sub': 12', '18, 'one or more of C-Calkyl, alkenyl, and acyl chains;'}polypropylene glycol (PPG); andpolycaprolactone (PCL).4. The artificial skin culture container according to claim 1 ,wherein, when 100 agar powders before the gelation of agar is defined as one unit, and the number of the hydrophobic molecules substituted into the agar powders in one unit is defined as the degree of substitution (%), the degree of substitution of hydrophobic molecules into the agar constituting the artificial skin culture container is 5.0% to 20%.5. The artificial skin culture container according to claim 1 ,wherein the proportion of hydrophobically-modified agar is 5 to 50% by weight based on the total ...

Подробнее
01-04-2021 дата публикации

METHOD AND SYSTEM FOR HAIR REGROWTH USING 3D ORGANOID SYSTEM OF HAIR FOLLICLE STEM CELL

Номер: US20210095253A1
Автор: Bang Dongha
Принадлежит:

A system and method for producing hair follicle stem cell 3D organoid using a feeder cell or cell line where the feeder cell or cell line is a dermal endothelial cell, a fibroblast cell or a cell line that is similar to the target cell or the same type of the target cell. The system and method provide rapid culture as well as a long-term sustainable 3D cell or tissue culture environment and also a treatment for hair loss. 2. The method according to claim 1 , wherein the second cell in the second medium is a dermal endothelial cell or a fibroblast cell.3. The method according to claim 1 , wherein the row hair follicle stem cell is from a scalp tissue of a patient and the second cell is an endothelial cell from the scalp tissue.4. The method according to claim 3 , wherein the second cell is an endothelial cell claim 3 , which has been subject to a 3D culture.5. A method for growing a 3D organoid of hair follicle stem cells claim 3 , comprisinga) preparing a first medium comprising a follicle stem cell from a patient;b) preparing a second medium comprising a dermal endothelial cell from the patientc) placing the first medium and the second medium in a grow substrate;d) placing a conditioned medium over the growing substrate to cover the first medium and the second medium, resulting in a culture plating;e) incubating the culture plating to grow the 3D organoid; andf) harvesting cultured hair follicle stem cells6. A method for promoting hair growth in a patient claim 3 , comprising injecting hair follicle stems cells derived from the patent into the patient's skin where the hair follicle stems cells are harvested from a culture bed comprising a hair follicle stem and a dermal endothelial cell from the patient wherein the dermal endothelial cell is a feeder cell.7. The method according to claim 6 , further comprising injecting dermal endothelial cells from the patient.8. The method according to claim 6 , wherein the dermal endothelial cells are harvested from a culture ...

Подробнее
01-04-2021 дата публикации

HIGHLY FUNCTIONAL MANUFACTURED STEM CELLS

Номер: US20210095254A1
Принадлежит:

Populations of synthetic ABCB5+ stem cells, wherein greater than 96.8% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5-positive mesenchymal stem cells are provided. Also provided are methods of making the synthetic cells and methods of use thereof. 1. A composition , comprising:a population of synthetic ABCB5+ stem cells, wherein greater than 96% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5-positive mesenchymal stem cells.2. The composition of claim 1 , wherein greater than 96.5% claim 1 , 97% claim 1 , 97.5% claim 1 , 98% claim 1 , 98.5% claim 1 , 99% claim 1 , 99.5% claim 1 , 99.7% claim 1 , 99.9% claim 1 , 99.99% claim 1 , 99.998% claim 1 , 99.999% claim 1 , or 99.999997% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5-positive mesenchymal stem cells.3. The composition of claim 1 , wherein 100% of the population is an in vitro progeny of physiologically occurring skin-derived ABCB5-positive mesenchymal stem cells.4. The composition of claim 1 , wherein greater than 90% of the synthetic stem cells in the population co-express CD90.5. The composition of claim 1 , wherein the population of synthetic stem cells are capable of VEGF secretion under hypoxia as measured by ELISA.6. The composition of claim 1 , wherein the population of synthetic stem cells are capable of IL-1RA secretion after co-culture with Mi-polarized macrophages.7. The composition of claim 1 , wherein the population of synthetic stem cells induce decreased TNF-alpha and IL-12/IL-23p40 secretion claim 1 , and increased IL-10 secretion claim 1 , in macrophage co-culture relative to isolated physiologically occurring skin-derived ABCB5-positive mesenchymal stem cells.8. The composition of claim 1 , wherein the population of synthetic stem cells possess multipotent differentiation capacity.9. The composition of claim 1 , wherein the population of synthetic stem cells possess the ...

Подробнее
26-03-2020 дата публикации

CELL SUSPENSION AND USE THEREOF

Номер: US20200093951A1
Автор: Quick Andrew
Принадлежит:

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for promoting tissue regeneration in an epithelium-related procedure, as well as compositions produced therefrom. The cellular suspension can include viable and functioning cells at various stages of differentiation, including undifferentiated/progenitor cells and differentiated cells, as well as those in between. In certain embodiments, the cellular suspension can be subjected to a stress to induce a heat shock response therein, or be exposed to an exogenously supplied agent such as heat shock protein or a fragment thereof, hyaluronic acid, platelet-enriched plasma, and/or growth factors. The cellular suspension can be applied directly to a patient's recipient site for in vivo regeneration, or be cultured or seeded to a matrix for in vitro growth/regeneration. 149-. (canceled)50. A method of preparing a cell suspension for tissue regeneration , the method comprising:collecting a population of cells from a skin tissue sample; andexposing the population of cells to platelet-enriched plasma.51. The method of claim 50 , wherein the skin tissue sample comprises an autologous epithelial tissue sample.52. The method of claim 50 , wherein the population of cells comprises viable and functioning cells from the skin tissue sample.53. The method of claim 52 , wherein the population of cells comprises keratinocytes claim 52 , melanocytes claim 52 , and fibroblasts.54. The method of claim 50 , wherein collecting the population of cells comprises exposing the skin tissue sample to an enzyme to dissociate cellular layers in the skin tissue sample.55. The method of claim 54 , wherein the enzyme comprises at least one enzyme selected from the group consisting of trypsin claim 54 , trypsin-EDTA claim 54 , dispase claim 54 , collagenase claim 54 , thermolysin claim 54 , pronase claim 54 , hyaluronidase claim 54 , elastase claim 54 , papain claim ...

Подробнее
26-03-2020 дата публикации

BIOCOMPATIBLE CONDITIONED CELL MEDIUM COMPOSITIONS AND USES THEREOF

Номер: US20200095539A1
Автор: Jin Richard C.
Принадлежит:

The present invention is drawn, in part, to biocompatible compositions comprising a biocompatible polymer matrix and conditioned cell medium comprising i) a cell culture medium and ii) one or more agents synthesized by and secreted from one or more cells cultured in the cell culture medium, as well as therapeutic uses thereof, particularly in modulating bone and/or gum tissue growth. 1. A biocompatible composition comprising:(a) a biocompatible polymer matrix; and(b) a conditioned cell medium comprising i) a cell culture medium and ii) one or more agents synthesized by and secreted from one or more cells cultured in the cell culture medium.2. The composition of claim 1 , wherein the cells are fibroblasts.3. The composition of claim 2 , wherein the fibroblasts are dermal fibroblasts.4. The composition of claim 3 , wherein the dermal fibroblasts are neonatal dermal fibroblasts.5. The composition of claim 1 , wherein the cells are osteoblasts.6. The composition of any one of - claim 1 , wherein the cells are fibroblasts and osteoblasts.7. The composition of any one of - claim 1 , wherein the cells are a co-culture of fibroblasts and osteoblasts.8. The composition of any one of - claim 1 , wherein the cells are actively proliferating cells.9. The composition of any one of - claim 1 , wherein the cell culture medium comprises a basal cell culture medium and further comprises one or more supplements selected from the group consisting of fetal bovine serum (FBS) claim 1 , L-glutamine claim 1 , human epidermal growth factor (EGF) claim 1 , basic fibroblast growth factor (bFGF) claim 1 , and ascorbic acid.10. The composition of claim 9 , wherein the basal cell culture medium is Dulbecco's modified eagle medium (DMEM).11. The composition of or claim 9 , wherein the supplement is a recombinant growth factor.12. The composition of claim 11 , wherein the recombinant growth factor is a human recombinant growth factor.13. The composition of any one of - claim 11 , wherein the one ...

Подробнее
23-04-2015 дата публикации

METHODS FOR USING AUTOLOGOUS FIBROBLASTS TO ALTER SKIN IDENTITY

Номер: US20150110750A1
Принадлежит:

The present invention relates to the field of autologous fibroblasts. More specifically, the present invention provides methods and compositions comprising autologous fibroblasts and uses thereof to alter skin identity. In certain embodiments, volar fibroblasts can be expanded for the ability to induce volar skin at the stump site in amputees. In other embodiments, fibroblasts from haired scalp can be expanded to ameliorate alopecias. 1. A method for altering skin identity in a patient comprising the step of transplanting autologous fibroblasts into the target skin site of a patient , wherein the autologous fibroblasts are obtained via a skin biopsy from the desired skin type site.2. The method of claim 1 , wherein the target skin site is the stump site skin of an amputee and the desired skin type site is volar skin of the amputee.3. The method of claim 1 , wherein the target skin site is an alopecia site on the patient and the desired skin type site is haired scalp.4. The method of claim 1 , wherein the target skin site is a scar and the desired skin type site is from an area adjacent to or surrounding the scar.5. The method of claim 1 , wherein the target skin site is discolored skin and the desired skin type is from an area adjacent to or surrounding the discolored skin.6. The method of claim 5 , wherein the discolored skin is a port wine stain.7. The method of claim 1 , wherein the target skin site is a mismatched split thickness skin graft or other autologous skin graft and the desired skin type is from the contralateral skin of desired identity.8. The method of claim 1 , wherein the target skin site is a site with a predilection for a rash or ulcer and the desired skin type is normally resistant to that rash or ulcer.9. The method of claim 8 , wherein the site with a predilection for a rash or ulcer is a pressure ulcer of the sacrum and the desired skin type that is normally resistant to that rash or ulcer is volar skin.10. A method for altering skin identify ...

Подробнее
19-04-2018 дата публикации

METHODS AND PRODUCTS FOR TRANSFECTION

Номер: US20180105800A1
Принадлежит:

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed. 19.-. (canceled)10. A method for reprogramming a non-pluripotent cell comprising:(a) providing a non-pluripotent cell;(b) culturing the non-pluripotent cell; and(c) transfecting the non-pluripotent cell with a synthetic RNA molecule, wherein:the synthetic RNA molecule encodes one or more reprogramming factor(s) selected from the group consisting of Oct4 protein, Sox2 protein, Klf4 protein, c-Myc protein, 1-Myc protein, Tert protein, Nanog protein, and Lin28 protein,the transfecting results in the non-pluripotent cell expressing the one or more reprogramming factor(s) which reprograms the non-pluripotent cell; andstep (c) is performed without using irradiated human neonatal fibroblast feeder cells and occurs in the presence of a medium containing ingredients that support reprogramming of the non-pluripotent cell.11. The method of claim 10 , wherein the non-pluripotent cell is derived from a biopsy.12. The method of claim 10 , wherein the non-pluripotent cell is harvested from a human subject.13. The method of claim 11 , wherein the non-pluripotent cell is harvested from a dermal punch biopsy sample.14. The method of claim 10 , wherein the non-pluripotent cell is a skin cell.15. The method of claim 10 , further comprising contacting the cell with at least one member of the group: poly-L-lysine claim 10 , poly-L-ornithine claim 10 , RGD peptide claim 10 , fibronectin claim 10 , vitronectin claim 10 , collagen claim 10 , and laminin.16. The method of claim 10 , wherein the synthetic RNA molecule contains at least one of a pseudouridine or a 5-methylcytidine residue.17. The method of claim 10 , wherein the medium is substantially free of immunosuppressants. The present ...

Подробнее
29-04-2021 дата публикации

ENGINEERED SKIN EQUIVALENT, METHOD OF MANUFACTURE THEREOF AND PRODUCTS DERIVED THEREFROM

Номер: US20210122922A1
Принадлежит:

Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same. 1198.-. (canceled)199. A composition comprising: an isolated artificial dermal layer comprising an immortalized keratinocyte cultured in vitro , and a scaffold , wherein the keratinocyte is at least partially in contact with the scaffold.200. The composition of claim 199 , wherein at least a portion of a cell layer has been removed.201. The composition of claim 199 , wherein the scaffold comprises a natural scaffold claim 199 , a synthetic scaffold or a combination thereof.202. The composition of claim 201 , comprising the synthetic scaffold.203. The composition of claim 201 , comprising the natural scaffold.204. The composition of claim 199 , wherein the scaffold comprises an at least partially hollow structure.205. The composition of claim 199 , wherein the scaffold comprises a collagen claim 199 , a cellulose claim 199 , a cotton claim 199 , an acetate claim 199 , an acrylic claim 199 , a latex claim 199 , a linen claim 199 , a nylon claim 199 , a rayon claim 199 , a velvet claim 199 , a modacrylic claim 199 , a saran claim 199 , a vinyon claim 199 , a wool claim 199 , a jute claim 199 , a hemp claim 199 , a bamboo claim 199 , a flax claim 199 , an alginate claim 199 , a fibronectin claim 199 , a poly-p-phenyleneterephthalamide claim 199 , a polyethylene claim 199 , a polypropylene claim 199 , a carrageenan claim 199 , an agarose claim 199 , a fibrin claim 199 , a glass claim 199 , a silica claim 199 , an aramid claim 199 , a carbon claim 199 , a poly(tetrafluoroethylene) claim 199 , a polyvinyl chloride claim 199 , a polyvinylidene chloride claim 199 , a polyvinyl alcohol claim 199 , a polyacrylonitrile claim 199 , a chitosan claim 199 , a polyurethane claim 199 , a poly(urethane-urea) claim 199 , a polyethylene phthalate claim 199 , a chitin claim 199 , a elastin claim 199 , a keratin ...

Подробнее
27-04-2017 дата публикации

ADULT STEM CELLS DERIVED FROM HUMAN SKIN DERMIS

Номер: US20170114326A1
Принадлежит:

Provided in the present invention are adult stem cells derived from human skin dermis, and a method for isolating same. Further provided in the present invention are osteoblastic cells and adipocytes differentiated from the adult stem cells derived from human skin dermis, and a differentiation method therefor. Further provided in the present invention is a composition for osteogenesis or lipogenesis containing the stem cells, osteoblastic cells, or adipocytes. The isolation method of the present invention enables the adult stem cells derived from human skin dermis to be obtained in an easy and simple manner at a high yield rate. Genes and growth factors which are specifically expressed in the adult stem cells derived from human skin dermis isolated using the method can be separated, identified, and used later. 1. A method for isolating human skin dermis-derived adult stem cells , comprising subculturing human skin dermis-derived fibroblasts , reacting the cells with gelatin or type 4 collagen for 1-5 minutes and separating the cells adhering to the gelatin or type 4 collagen.2. The method for isolating human skin dermis-derived adult stem cells according to claim 1 , wherein the gelatin is dissolved in distilled water to a concentration of 0.1-1 wt % and the type 4 collagen is dissolved in distilled water to a concentration of 10-30 μg/mL and then reacted with the fibroblasts.3. The method for isolating human skin dermis-derived adult stem cells according to claim 1 , wherein the gelatin or the type 4 collagen is coated on a substrate at 0-10° C. for 16-24 hours and then reacted with the fibroblasts.4. The method for isolating human skin dermis-derived adult stem cells according to claim 1 , which further comprises confirming whether one or more gene selected from a group consisting of Sox2 (SRY (sex determining region Y)-box 2) and S100b (S100 calcium binding protein B) is overexpressed as compared to skin dermis-derived fibroblasts.5. The method for isolating ...

Подробнее
05-05-2016 дата публикации

GENETICALLY-MODIFIED MICRO-ORGAN SECRETING A THERAPEUTIC PEPTIDE AND METHODS OF USE THEREOF

Номер: US20160122713A1
Принадлежит: Medgenics Medical Israel Ltd.

Provided herein is a genetically-modified micro-organ that provides a sustained delivery of a therapeutic peptide. The genetically-modified micro-organ may comprise a viral vector or expression cassette comprising at least two nucleic acid sequences encoding the therapeutic peptide separated by a cleavable linker. Further provided herein is a method of treating or preventing a disease or disorder in a human subject that can be treated or prevented by administration of a therapeutic peptide over a sustained time period using the genetically-modified micro-organ described herein. 1. A genetically-modified micro-organ that provides a sustained delivery of at least one therapeutic peptide when implanted in a human subject in vivo comprising a viral vector comprising at least two nucleic acid sequences encoding at least one therapeutic peptide separated by at least one cleavable linker , wherein the genetically-modified micro-organ provides the peptide as a monomer for a sustained period of at least three months as measured in vitro or in vivo.2. A genetically-modified micro-organ that provides a sustained delivery of at least one therapeutic peptide when implanted in a human subject in vivo , comprising a nucleic acid expression cassette comprising at least two nucleic acid sequences encoding at least one therapeutic peptide separated by at least one cleavable linker , wherein the genetically-modified micro-organ provides the peptide as a monomer for a sustained period of at least three months as measured in vitro or in vivo.3. The genetically-modified micro-organ of claim 2 , wherein there are at least two copies of the therapeutic peptide claim 2 , and wherein the peptide is expressed first as a polypeptide claim 2 , and wherein the polypeptide is cleaved by an endogenous protease in vivo to produce at least two peptide monomers.4. The genetically-modified micro-organ of claim 2 , wherein the sustained period of at least three months is measured in vivo in serum.5. ...

Подробнее
05-05-2016 дата публикации

SERUM-FREE MEDIUM CONTAINING PDGF FOR DS CELLS

Номер: US20160122714A1
Принадлежит: SHISEIDO COMPANY, LTD.

The problem to be solved by the present invention is to provide a serum-free medium suitable for culturing of DS cells. The present invention relates to a serum-free medium for culturing of DS cells containing platelet-derived growth factor (PDGF), or to a method for culturing of dermal sheath (DS) cells, using serum-free medium comprising PDGF. 1. A serum-free medium for culturing of dermal sheath (DS) cells , comprising platelet-derived growth factor (PDGF).2. The serum-free medium according to claim 1 , wherein the PDGF is PDGF-BB.3. The serum-free medium according to claim 1 , wherein the dermal sheath (DS) cells are derived from the dermal sheath cup (DSC) region.4. A method for culturing dermal sheath (DS) cells claim 1 , using a serum-free medium comprising platelet-derived growth factor (PDGF).5. The method according to claim 4 , wherein the PDGF is PDGF-BB.6. The method according to claim 4 , wherein the dermal sheath (DS) cells are derived from the dermal sheath cup (DSC) region. The present invention relates to a serum-free medium for culturing of DS cells, comprising platelet-derived growth factor (PDGF), and to a method for culturing of dermal sheath (DS) cells, using serum-free medium comprising PDGF.Hair is considered very important for aesthetic outer appearance. Therefore, alopecia or hair loss due to congenital or acquired causes can be seriously distressing for individuals. Particularly in modern society, which has been referred to as an “aging society” or “stress society”, there is increasing risk of alopecia of head hair due to a variety of acquired causes. Many attempts have been made in response to this situation, to provide cosmetic or medical methods for safely and effectively regenerating hair follicles in individuals suffering from alopecia or hair loss.Hair follicles are exceptional organs that repeat self-regeneration in the mature body essentially throughout the entire lifetime. Elucidating the mechanism of this self-regeneration is ...

Подробнее
24-07-2014 дата публикации

COMPOSITIONS DERIVED FROM STEM CELL RELEASED MOLECULES & METHODS FOR FORMULATION THEREOF

Номер: US20140205563A1
Принадлежит: BioRegenerative Sciences, Inc.

Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (SRM's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and SRM's can be derived from one or more distinct cell lines. The SRM's can further include one or more mucins, cytokines, or growth factors. Exemplary formulations include stem cells and SRMs derived from epithelial stem cells, corneal limbal stem cells, and fibroblasts. Other compositions and methods for formulation thereof are described. 1. A therapeutic composition for hair growth treatment , comprising:an amount of stem cells and stem cell released molecules derived from a first cell line collectively defining a first adjuvant material, wherein said first cell line comprises one of: mesenchymal stem cells, epithelial stem cells, limbal stem cells, or fibroblasts;an amount of stem cells and stem cell released molecules derived from a second cell line and a third cell line collectively defining a second adjuvant material, wherein said second or third cell line each comprises one of: mesenchymal stem cells, epithelial stem cells, limbal stem cells, or fibroblasts, and wherein each of said second cell line said third cell line is distinct from said first cell line; anda thickening agent comprising at least one of a cellulosic material or a polymer;said first adjuvant material, second adjuvant material, and thickening agent being combined in an aqueous solution.2. The composition of claim 1 , wherein said stem cell released molecules comprise at least one of: cytokines claim 1 , anti-oxidants claim 1 , micro-RNA claim 1 , growth factors claim 1 , and mucins.3. The composition of claim 2 , wherein said cytokines include one or more of: interleukin (IL)-2 claim 2 , IL-4 claim 2 , IL-5 claim 2 , IL-6 claim 2 , IL-10 claim 2 , interferon (IFN)-gamma claim 2 , tumor necrosis factor (TNF)-alpha claim 2 , and IL-1 beta.4. The composition of claim 2 ...

Подробнее
19-05-2016 дата публикации

SKIN PRINTING AND AUTO-GRAFTING

Номер: US20160137979A1
Принадлежит:

A holey substrate now is used for constructing a graft product, such as building an auto-graft by 3D printing of living cells. When the autograft built atop the holey substrate is implanted, blood vessels and other patient tissues can grow through the holes. 12-. (canceled)32. The method of claim , wherein the printing step comprises printing onto a honeycomb-shaped substrate that comprises a plurality of hexagon-shaped holes , wherein a hexagon-shaped hole has a width of about 3 mm.4. (canceled)5. The method of wherein the step of printing cells comprises printing dermal cells.6. The method of claim 9 , wherein before the printing step claim 9 , cells are harvested from a patient and the 3D printer is stocked with the harvested cells.7. The method of claim 9 , wherein the printing step comprises printing onto a holey substrate that consists of a resorbable material that a human body resorbs in a period of weeks or months.8. The method of claim 9 , wherein the printing step comprises printing onto a holey substrate that has a thickness in a range of about 1-3 microns.9. A cell printing method claim 9 , comprising:printing, performed by a 3D printer stocked with a quantity of living cells, cells in tracks onto a holey substrate, wherein the holey substrate is characterized by a plurality of holes.10. The cell printing method of claim 9 , wherein the holey substrate is a honeycomb-patterned substrate.11. The cell printing method of claim 9 , comprising printing cells in layers.12. The cell printing method of claim 11 , comprising printing different numbers of layers of cells in different areas of the substrate.13. The cell printing method of claim 9 , comprising printing collagen onto the holey substrate claim 9 , followed by printing fibroblasts onto the collagen.1422-. (canceled)23. The method of claim 9 , wherein the printing step comprises printing a layer of living cells onto a structural material claim 9 , directly.24. The method of claim 9 , wherein the ...

Подробнее
03-06-2021 дата публикации

PREMATURE INFANT SKIN MODEL AND METHOD OF CREATING THE SAME

Номер: US20210163889A1
Принадлежит: KIMBERLY-CLARK WORLDWIDE, INC.

A premature infant skin model and methods of creating the same are disclosed. One method of creating a three-dimensional premature infant skin model can include providing neonatal skin cells, exposing the neonatal skin cells to a treatment solution including interleukin-6 for a treatment period; and removing the treatment solution from the neonatal skin cells after the treatment period to provide the three-dimensional premature infant skin model. 1. A method of creating a premature infant skin model , the method comprising:providing neonatal skin cells;exposing the neonatal skin cells to a treatment solution comprising interleukin-6 for a treatment period; andremoving the treatment solution from the neonatal skin cells after the treatment period to provide the three-dimensional premature infant skin model.2. The method of claim 1 , wherein the neonatal skin cells comprise neonatal dermal skin cells and neonatal epidermal skin cells.3. The method of claim 1 , wherein exposing the neonatal skin cells to a treatment solution comprising interleukin-6 comprises culturing the neonatal skin cells at an air-liquid interface.4. The method of claim 1 , wherein the treatment period is less than seven days.5. The method of claim 1 , wherein the treatment period is greater than one day.6. The method of claim 1 , wherein the treatment period is between two to six days.710. The method of claim 1 , wherein the interleukin-6 is provided at a concentration of from about ng/mL to about 100 ng/mL by total weight/volume of the treatment solution.8. The method of claim 1 , wherein the treatment solution further comprises a base medium of Dulbecco's Modified Eagles Medium and at least one growth factor.9. The method of claim 2 , further comprising:culturing the neonatal dermal skin cells in a culture medium for an initial culture period; andadding the neonatal epidermal skin cells on top of the neonatal dermal skin cells after the initial culture period for a secondary culture period.10. ...

Подробнее
03-06-2021 дата публикации

Cell-Containing Hydrogel Body and Method for Producing Same

Номер: US20210163918A1
Принадлежит:

Provided are a cell-containing hydrogel body and a method of producing the same, which enable simple and effective control of the size of a boundary surface for an interaction between cells. The method of producing a cell-containing hydrogel body includes: forming, under a gas phase, a first hydrogel droplet on a surface of a substrate, the first hydrogel droplet containing first cells being dispersed therein and a first hydrogel polymer; forming, under a gas phase, a second hydrogel droplet on the surface, the second hydrogel droplet containing second cells being dispersed therein and a second hydrogel polymer, the second hydrogel droplet being combined with the first hydrogel droplet; and forming, under a gas phase, a cell-containing hydrogel body on the surface by gelling a hydrogel droplet-combined body including a first droplet portion derived from the first hydrogel droplet and a second droplet portion derived from the second hydrogel droplet. 1. A method of producing a cell-containing hydrogel body , comprising:forming, under a gas phase, a first hydrogel droplet on a surface of a substrate, the first hydrogel droplet containing first cells being dispersed therein and a first hydrogel polymer;forming, under a gas phase, a second hydrogel droplet on the surface, the second hydrogel droplet containing second cells being dispersed therein and a second hydrogel polymer, the second hydrogel droplet being combined with the first hydrogel droplet; andforming, under a gas phase, a cell-containing hydrogel body on the surface by gelling a hydrogel droplet-combined body including a first droplet portion derived from the first hydrogel droplet and a second droplet portion derived from the second hydrogel droplet.2. The method of producing a cell-containing hydrogel body according to claim 1 , further comprising culturing the first cells and the second cells in the cell-containing hydrogel body.3. The method of producing a cell-containing hydrogel body according to claim ...

Подробнее
18-05-2017 дата публикации

AUTO-GRAFTING

Номер: US20170136148A1
Принадлежит:

An apparatus and method for the production of substitute skin that advantageously reduces the amount of donor dermal cells needed from non-wound areas of a patient having a wound to be auto-grafted is reduced by using all of the harvested skin cells. A 3D printer is used to construct a wound graft product from the harvested skin cells without wasting any of the harvested skin cells. In a case of an irregularly shaped wound, wastage of harvested skin associated with trimming is avoided. 148-. (canceled)49. An auto-grafting method for treating a wound of a patient , comprising:harvesting a quantity of skin cells from a patient;auto-grafting onto the wound of the patient the quantity of harvested skin cells, with the quantity of autografted harvested skin cells being substantially equal to the quantity of harvested skin cells.50. The auto-grafting method of claim 49 , wherein the auto-grafting step comprises auto-grafting a three-dimensional irregularly-shaped skin graft product.51. The auto-grafting method of claim 49 , further comprising constructing claim 49 , via operation of a three-dimensional printer claim 49 , a skin graft product comprising the quantity of harvested skin cells.5221. The method of claim claim 49 , further comprising printing insulin into the skin graft product being constructed.5321. The method of claim claim 49 , further comprising printing or spraying amniotic membrane into the skin graft product being constructed. The invention relates to the medical arts, more particularly, to tissue engineering especially tissue engineering in which three-dimensional printing technology is used.Healing wounds is a complex process of tissue repair and regeneration in response to injury. The healing response in skin wounds attempts to reconstitute a tissue similar to the original damaged one and this is accomplished via the concerted action of numerous skin cell types, collagens, cytokines, growth factors (GFs), chemokines, cell surface and adhesion ...

Подробнее
30-04-2020 дата публикации

Culture System and Media for Skin Explants Providing Enhanced Viability and Enabling Molecular Studies

Номер: US20200131483A1
Принадлежит:

Embodiments of the invention include systems and media for mammalian cell culture that enhance cell viability which enables biological assays and quantitative studies in tissues such as skin explants. Certain embodiments may be used in coordination with each other or may be practiced separately. An exemplary embodiment of the invention is a culture medium that includes Dulbecco's Modified Eagle's Medium, X-VIVO medium, and subcutaneous adipocyte medium. In one embodiment the culture medium includes approximately 30-60% Dulbecco's Modified Eagle's Medium by volume, approximately 30-60% X-VIVO medium by volume, and approximately 2.5-15% subcutaneous adipocyte medium by volume. Certain embodiments of the culture medium can also include recombinant human stem cell factor. Embodiments of the invention disclosed here are not limited to the brands described and encompass equivalents, as well as combinations, of the individual chemical components that make up the media described herein. 1. A culture medium comprising:Dulbecco's Modified Eagle's Medium,X-VIVO medium, andsubcutaneous adipocyte medium.2. The culture medium of claim 1 , further comprising recombinant human stem cell factor.3. The culture medium of claim 2 , wherein the recombinant human stem cell factor is present in an amount ranging from about 100 nanograms/milliliter to 300 nanograms/milliliter based on the volume of X-VIVO medium.4. The culture medium of claim 1 , wherein the culture medium comprises:approximately 30.00-60.00% Dulbecco's Modified Eagle's Medium by volume,approximately 30.00-60.00% X-VIVO medium by volume, andapproximately 2.50-15.00% subcutaneous adipocyte medium by volume.5. The culture medium of claim 4 , wherein the culture medium comprises:approximately 35.00-55.00% Dulbecco's Modified Eagle's Medium by volume,approximately 35.00-55.00% X-VIVO medium by volume,approximately 5.00-12.50% subcutaneous adipocyte medium by volume, andapproximately 125-275 ng/mL recombinant human stem cell ...

Подробнее
02-06-2016 дата публикации

Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5 and LGR6 Expressing Epithelial Stem Cells

Номер: US20160151540A1
Автор: Denver M. Lough
Принадлежит: Individual

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application.

Подробнее
07-06-2018 дата публикации

Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5, and LGR6 Expressing Epithelial Stem Cells

Номер: US20180154043A1
Автор: Lough Denver M.
Принадлежит:

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application. 1. A minimally polarized micro-aggregate multi-cellular composition , comprising: a multi-dimensional support selected from the group consisting of scaffolding , collagen , matrix , particle , and fiber , and isolated living LGR expressing cells.2. The composition of further including growth factors and the LGR expressing cells being selected from the group consisting of LGR4 claim 1 , LGR5 and LGR6.3. The composition of further including migratory/recruiting analytes and the LGR expressing cells being selected from the group consisting of LGR4 claim 1 , LGR5 and LGR6.4. The composition according to of further including LGR specific binding elements selected from the group consisting of ligand families claim 1 , R-spondin claim 1 , EDGF claim 1 , PDGF claim 1 , Wnt claim 1 , VEGF claim 1 , and antimicrobial peptides and where the LGR expressing cells are selected from the group consisting of LGR4 claim 1 , LGR5 and LGR6.5. A composition according to where the composition is used for a therapeutic construct for any one of a tissue region claim 1 , wound claim 1 , void claim 1 , defect tissue claim 1 , or blood.6. A composition according to where the composition is used as a therapeutic construct for alteration of surrounding adjacent tissues.7. A composition according to where the multi-dimensional support and isolated living LGR expressing cells providing a micro-aggregate multi-cellular construct for accelerated healing of wounds.8. A ...

Подробнее
07-06-2018 дата публикации

Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5, and LGR6 Expressing Epithelial Stem Cells

Номер: US20180154044A1
Автор: Lough Denver M.
Принадлежит:

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application. 19-. (canceled)10. A method for obtaining a minimally polarized micro-aggregate multi-cellular composition characterized by the steps of growing and isolating living LGR expressing cells for transplantation to a select mammalian target tissue.11. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition according to further characterized by the step of affixing the isolated living LGR expressing cells to a multi-dimensional support selected from the group consisting of scaffolding claim 10 , collagen claim 10 , matrix claim 10 , particle claim 10 , and fiber.12. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition according to further characterized by the step of selecting the LGR expressing cells from the group consisting of LGR4 claim 10 , LGR5 and LGR6.13. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition of further characterized by the step of applying the minimally polarized micro-aggregate multi-cellular composition directly to a tissue in vivo for tissue restoration.14. The method for obtaining a minimally polarized micro-aggregate multi-cellular composition of further characterized by the step indirectly applying the minimally polarized micro-aggregate multi-cellular composition via the blood stream for tissue restoration in a body.15. The method for obtaining a minimally polarized micro-aggregate multi-cellular ...

Подробнее
23-05-2019 дата публикации

METHOD FOR ENZYMATIC TREATMENT OF TISSUE PRODUCTS

Номер: US20190151507A1
Принадлежит:

Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating a tissue matrix with a proteolytic enzyme to produce a desired pliability of the tissue matrix and/or to control the immunogenicity of the tissue matrix. The methods can comprise treatment with alcalase under conditions controlled to produce a desired pliability without unacceptable alteration in collagen structure. 1. A method for treating a tissue matrix , comprising:selecting a tissue;contacting the tissue with a first solution comprising an effective amount of alcalase under conditions including an incubation time in the first solution having an alcalase activity selected to produce an increase in pliability of the tissue without producing significant collagen degradation to produce an alcalase-treated tissue; andtreating the alcalase-treated tissue with a second solution to decellularize the alcalase-treated tissue to produce an acellular tissue matrix.2. The method of claim 1 , wherein the tissue is a non-primate tissue.3. The method of claim 1 , wherein the tissue is a porcine tissue.4. The method of claim 1 , wherein the first solution comprises alcalase with an activity of 1×10Anson units/mL to 0.015 Anson units/mL.5. The method of claim 1 , wherein the first solution comprises alcalase with an activity of 1×10Anson units/mL to 1.5×10Anson units/mL.6. The method of claim 1 , wherein the first solution comprises alcalase with an activity of about 2×10Anson units/mL to about 4×10Anson units/mL.7. The method of claim 1 , further comprising packaging the tissue matrix.8. The method of claim 7 , further comprising sterilizing the tissue matrix.9. The method of claim 1 , wherein the tissue is contacted with alcalase under conditions to produce reductions in the drape value of or at least 30%.10. The method of claim 1 , wherein the tissue is contacted with alcalase under conditions to produce reductions in the drape value of or ...

Подробнее
23-05-2019 дата публикации

SYSTEM AND METHOD FOR EXTRACTING BIOLOGICAL MATERIALS FROM HARVESTED SKIN

Номер: US20190151508A1
Автор: Rotunda Adam M.
Принадлежит:

Systems and methods for extracting and isolating components from a patient's dermis for autologous use are contemplated wherein dermal micrografts or microplugs are harvested from a patient via an arrayed transection process and subsequently homogenized and centrifuged. Such a process may permit skin components to be obtained in a minimally invasive and rapid fashion, including fat, collagen, fibroblasts, adipocytes, or plasma. For procedures in which only modest quantities of materials are required and benefits may be realized from using autologous materials, the disclosed techniques may be ideal. 1. A method of extracting and isolating fat from a patient's dermis for autologous use , the method comprising the steps of:harvesting a plurality of dermal grafts from a patient, the plurality of dermal grafts being obtained via an arrayed transection process;homogenizing the dermal grafts;centrifuging the homogenized dermal grafts; andisolating the fat component of the centrifuged, homogenized dermal grafts.2. The method of claim 1 , wherein the harvesting step is performed via an arrayed transection process operative to produce a plurality of elliptical dermal grafts claim 1 , the mean diameter of the respective ones of the plurality of elliptical dermal grafts being between ½ mm and 1 mm.3. The method of wherein the elliptical dermal grafts are circular.4. The method of claim 1 , wherein the harvesting step is performed via an arrayed transection process operative to produce a plurality of quadrilateral dermal grafts claim 1 , the mean length of the smallest side of the respective ones of the plurality of quadrilateral dermal grafts being less than 1 mm.5. The method of claim 4 , wherein the quadrilateral dermal grafts are square.6. A method of extracting and isolating collagen from a patient's dermal for autologous use claim 4 , the method comprising the steps of:harvesting a plurality of dermal grafts from a patient, the plurality of dermal grafts being obtained via ...

Подробнее
14-05-2020 дата публикации

COMPOSITIONS AND METHODS FOR OBTAINING FUNCTIONAL BASAL-LIKE CELLS

Номер: US20200149004A1
Принадлежит:

The invention disclosed herein generally relates to methods and systems for converting stem cells into specific tissue(s) or cells through directed differentiation. In particular, the invention disclosed herein relates to methods and systems for promoting functional basal-like cells from pluripotent stem cell-derived lung bud tip progenitor organoid tissue through activation of SMAD signaling via activation of TGFβ1 (and/or the TGFβsignaling pathway) and BMP4 (and/or the BMP signaling pathway). 1. A method , comprising:culturing pluripotent stem cell-derived lung bud tip progenitor organoid tissue in vitro, wherein the culturing results in differentiation of the pluripotent stem cell-derived lung bud tip progenitor organoid tissue into functional basal-like cells, wherein the culturing comprises activation of SMAD signaling within the pluripotent stem cell-derived lung bud tip progenitor organoid tissue; andobtaining functional basal-like cells from the cultured pluripotent stem cell-derived lung bud tip progenitor organoid tissue.2. The method of claim 1 ,wherein activation of SMAD signaling comprises activation of TGFβ1 (and/or the TGFβsignaling pathway) and BMP4 (and/or the BMP signaling pathway).3. The method of claim 2 ,wherein activation of TGFβ1 (and/or the TGFβsignaling pathway) is accomplished with a small molecule or agonist.4. The method of claim 3 , wherein activation of the TGFβsignaling pathway is accomplished with TGFβ1 claim 3 , TGFβ2 claim 3 , or TGFβ3.5. The method of claim 2 ,wherein activation of the BMP signaling pathway is accomplished with a small molecule or agonist.6. The method of claim 5 , wherein activation of the BMP signaling pathway is accomplished with BMP2 claim 5 , BMP3 claim 5 , BMP4 claim 5 , BMP5 claim 5 , BMP6 claim 5 , BMP7 claim 5 , BMP8a and 8b claim 5 , BMP10 claim 5 , BMP11 or BMP15.7. The method of claim 1 , wherein the obtained functional basal-like cells have one or more of the following characteristics: increased TP63 ...

Подробнее
16-06-2016 дата публикации

ADHEREND RECOVERY METHOD, ADHEREND RECOVERY APPARATUS, GAS-GENERATING FILM AND RESIN COMPOSITION

Номер: US20160168532A1
Принадлежит: JSR Corporation

The invention is an adherend recovery method capable of recovering adherends such as cells no matter the types of adherends. 1. An adherend recovery method for recovering an adherend from a support , comprising:a step (I) of exposing a stack disposed on the support, the stack including a photosensitive gas generation layer, an adhesive layer and the adherend in this order on the support, a step (II) of generating a gas from the photosensitive gas generation layer to separate the support and the stack from each other by the action of the gas, and a step (III) of recovering the adherend from the support by recovering the stack separated.2. The adherend recovery method according to claim 1 , wherein the photosensitive gas generation layer includes at least one selected from azides and diazo compounds.3. The adherend recovery method according to claim 1 , wherein the photosensitive gas generation layer includes an elastomer.4. The adherend recovery method according to claim 1 , wherein the photosensitive gas generation layer includes a polymer containing a (meth)acrylic structural unit.5. The adherend recovery method according to claim 4 , wherein the photosensitive gas generation layer comprises 5 to 20 parts by mass of the at least one selected from azides and diazo compounds based on 100 parts by mass of the polymer containing a (meth)acrylic structural unit.6. The adherend recovery method according to claim 1 , wherein the adherend is a cell.7. The adherend recovery method according to claim 1 , wherein a plurality of stacks are disposed on the support and a desired adherend is selectively recovered from the support by selectively exposing the target stack.8. An adherend recovery apparatus comprising:(1) a substrate including a stack, the stack includes a support, a photosensitive gas generation layer and an adhesive layer in this order,(2) a stage on which the substrate is placed,(3) a device configured to supply a target substance to the substrate,(4) a detection ...

Подробнее
21-05-2020 дата публикации

STEM CELL-DERIVED SKIN PRECURSOR CELL CULTURE MEDIUM AND PREPARATION METHOD THEREFOR

Номер: US20200157500A1
Автор: KIM Ae Ri, YU Ji Min
Принадлежит: CHA BIOTECH CO., LTD.

Provided are a method of preparing a stem cell-derived epidermal progenitor cell conditioned medium, the method including: differentiating stem cells to stem cell-derived epidermal progenitor cells by culturing the stem cells in a differentiation medium containing ascorbic acid and hydrocortisone; producing a culture of stem cell-derived epidermal progenitor cells by culturing the differentiated stem cell-derived epidermal progenitor cells in a medium; and recovering the stem cell-derived epidermal progenitor cell conditioned medium from the culture of the stem cell-derived epidermal progenitor cells, a stem cell-derived epidermal progenitor cell conditioned medium prepared by the method, and a method of producing a protein from stem cell-derived epidermal progenitor cells, the method including the method of preparing the stem cell-derived epidermal progenitor cell conditioned medium. 1. A method of preparing a stem cell-derived epidermal progenitor cell conditioned medium , the method comprising:differentiating stem cells to stem cell-derived epidermal progenitor cells by culturing the stem cells in a differentiation medium containing ascorbic acid and hydrocortisone;producing a culture of stem cell-derived epidermal progenitor cells by culturing the differentiated stem cell-derived epidermal progenitor cells in a medium; andrecovering the stem cell-derived epidermal progenitor cell conditioned medium from the culture of the stem cell-derived epidermal progenitor cells.2. The method of claim 1 , wherein a concentration of ascorbic acid is in a range of 0.03 μM to 3 μM claim 1 , and a concentration of hydrocortisone is in a range of 0.05 μg/ml to 5 μg/ml.3. The method of claim 1 , wherein the differentiating of the stem cells to the stem cell-derived epidermal progenitor cells is performed by culturing for 120 hours to 600 hours.4. The method of claim 1 , wherein the stem cells comprise one or more cells from embryonic stem cells claim 1 , adult stem cells claim 1 , ...

Подробнее
30-05-2019 дата публикации

SPHEROID TISSUE MICROARRAY AND METHODS OF MANUFACTURE

Номер: US20190162637A1
Автор: Plummer Simon M.
Принадлежит: Micromatrices Associates Ltd.

A spheroid tissue microarray comprises an array of tissue spheroids embedded within a porous mold. The product may be impregnated with a wax or resin and sectioned, and contains spheroids which are precisely located in a regular geometric grid. A method of manufacturing a spheroid tissue microarray comprises the steps of: forming a mold of porous material from liquid mold material in a casting mold, and allowing the liquid mold material to set; removing the porous mold from the casting mold; topping up the porous mold with further liquid mold material, and allowing recesses to form in the surface of the mold by the drawing-in of liquid mold material through shrinkage as the liquid mold material sets; placing tissue spheroids into the recesses in the surface of the porous mold; and sealing the tissue spheroids within the mold by topping off with liquid mold material and allowing the liquid mold material to set. An alternative method comprises the steps of: forming a mold of porous material from liquid mold material in a casting mold; allowing the liquid mold material to set; removing the porous mold from the casting mold; placing spheroids in recesses at the bases of wells in the mold of porous material; and sealing the spheroids within the porous mold by adding further porous material on top of the spheroids; wherein the recesses at the bases of the wells in the porous material are formed by protrusions of the casting mold carrying further, nipple-shaped, protrusions. 1. A spheroid tissue microarray comprising an array of tissue spheroids embedded within a porous mold.2. The spheroid tissue microarray according to wherein the porous mold is formed from an agarose or agar gel.3. The spheroid tissue microarray according to which is formed to contain a series of regularly positioned holes arranged in a grid pattern.4. The spheroid tissue microarray according to wherein the holes are between 0.2 and 3.0 mm diameter.5. (canceled)6. (canceled)7. The spheroid tissue ...

Подробнее
06-06-2019 дата публикации

POLYPEPTIDE DERIVED FROM TROPOELASTIN AND BIOCOMPATIBLE MATERIAL COMPRISING SAME

Номер: US20190169269A1
Принадлежит:

The present invention provides a tropoelastin-derived polypeptide and an elastic composite biocompatible material comprising the polypeptide. The object of the invention is also a method for the synthesis of such a biocompatible material, a cell culture support comprising such a biocompatible material and the use of this material, in particular in the biological and medical field, in particular for cell culture and tissue regeneration. 3. Polypeptide according to claim 1 , comprising the amino acid sequence SEQ ID No. 8.4. Biocompatible material comprising a polypeptide according to .5. Biocompatible material according to claim 4 , characterized in that it further comprises a hydrophilic polymer.6. Biocompatible material according to characterized in that:the polypeptide comprises the amino acid sequence SEQ ID No. 8,the polymer is a grafted dendrimer of polylysine of generation 3, and the biocompatible material comprises a bifunctional crosslinking agent comprising a polyethylene glycol (PEG) chain.7. Composite biomaterial comprising a biocompatible material according to claim 5 , and a compound consisting of a synthetic material claim 5 , a material of natural origin claim 5 , or a mixture of a synthetic material and a material of natural origin.8. Method for preparing a biocompatible material according to claim 5 , comprising a step of mixing a polypeptide according to and a crosslinking agent.9. Method according to claim 8 , wherein the crosslinking agent is a bifunctional agent and wherein the step of mixing the polypeptide and the crosslinking agent is carried out in the presence of a hydrophilic polymer.10. Method according to comprising a step of casting the biocompatible material in a mold of defined shape claim 8 , and a step of generating pores within the material claim 8 , wherein the two steps may be successive claim 8 , in any what order claim 8 , or simultaneous.11. Method according to further comprising a step of contacting the mixture of a ...

Подробнее
18-09-2014 дата публикации

Self-Organized Vascular Networks from Human Pluripotent Stem Cells in a Synthetic Matrix

Номер: US20140273220A1
Принадлежит: JOHNS HOPKINS UNIVERSITY

A bicellular vascular population derived from human pluripotent stem cells (hPSCs) undergoes morphogenesis and assembly in a synthetic hydrogel. It is shown that hPSCs can be induced to co-differentiate into early vascular cells (EVCs) in a clinically-relevant strategy dependent upon Notch activation. These EVCs mature into ECs and pericytes, and self-organize to form vascular networks in an engineered matrix. Upon in vivo implantation, multicellular human vascular networks are functionally perfused. Thus, a derived bicellular population is exploited for its intrinsic self-assembly capability to create functional microvasculature in a deliverable matrix.

Подробнее
18-06-2020 дата публикации

DECELLULARIZED BIOMATERIAL FROM NON-MAMMALIAN TISSUE

Номер: US20200188557A1
Автор: Early Ryanne
Принадлежит:

The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and on-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, durations and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue. 1. Decellularized extracellular matrix (ECM) derived from a Urodele said decellularized ECM derived by:a. obtaining a tissue sample from a urodele, which tissue sample comprises ECM; andb. decellularizing said tissue sample to produce decellularized ECM by removing sufficient cellular components of the sample to reduce or eliminate antigenicity of the biomaterial making it suitable for use as a xenograft.2. The decellularized ECM of claim 1 , wherein said decellularizing comprises subjecting said tissue sample to an alkaline treatment.3. The decellularized ECM of claim 1 , wherein said decellularized ECM is subjected to sterilization.4. The decellularized ...

Подробнее
13-08-2015 дата публикации

Methods for Efficient Immortalization Of Normal Human Cells

Номер: US20150225696A1
Принадлежит:

Methods for inducing non-clonal immortalization of normal epithelial cells by directly targeting the two main senescence barriers encountered by cultured epithelial cells. In human mammary epithelial cells (HMEC), the stress-associated stasis barrier was bypassed and the replicative senescence barrier, a consequence of critically shortened telomeres, was bypassed in post-stasis HMEC. Early passage non-clonal immortalized lines exhibited normal karyotypes. Methods of efficient HMEC immortalization, in the absence of “passenger” genomic errors, should facilitate examination of telomerase regulation, immortalization during human carcinoma progression, and methods for screening for toxic and environmental effect on progression. 1. A method to efficiently and reproducibly immortalize normal human mammary epithelial cells (HMEC) , the method comprising the steps of:a) providing HMEC in a low stress-inducing medium;b) introducing into pre-stasis HMEC a first pre-stasis polynucleotide construct that prevents the cell-cycle control protein Retinoblastoma (RB) from staying in an active form and allowing said HMEC to enter stasis, wherein such introduction occurs prior to the induction of Cyclin-dependent kinase inhibitor 2A (p16) and induces errors that bypass or overcome the RB block and stasis;c) providing HMEC that have entered stasis from the previous step, wherein the HMEC have entered stasis by bypassing and overcoming the RB block;d) introducing into the post-stasis HMEC a post-stasis polynucleotide construct that will induce expression of human telomerase reverse transcriptase (hTERT) and/or telomerase activity, wherein such introduction of the post-stasis polynucleotide construct occurs prior to telomere dysfunction from eroded telomeres, and whereby said introduction induces errors that reactivate sufficient telomerase activity; ande) reactivating telomerase activity thereby inducing immortalization of said post-stasis HMEC.2. The method of wherein the low-stress ...

Подробнее
20-08-2015 дата публикации

Method for isolation and purification of epithelial stem cells from skin

Номер: US20150232807A1
Принадлежит: PELL CELL MEDICALS NV

The current invention concerns a method for obtaining a cellular composition comprising epithelial stem cells (EpSCs) from mammalian skin, whereby said composition comprises at least 90% of viable EpSCs, comprising the steps of:—obtaining a mammalian skin sample;—obtaining a cell suspension from said skin sample by performing at least one enzymatic dissociation step; and—culturing said cell suspension under low-attachment conditions. Preferably cellular composition comprises epithelial stem cells derived from the epidermal layer. In a second aspect, the current invention provides for a cellular composition obtained by the method according to the invention.

Подробнее
16-08-2018 дата публикации

METHODS AND PRODUCTS FOR TRANSFECTION

Номер: US20180230438A1
Принадлежит:

The present invention relates in pan to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed. 19.-. (canceled)10. A method for reprogramming a differentiated cell to a less differentiated state , comprising:(a) providing a differentiated cell;(b) culturing the differentiated cell;(c) transfecting the differentiated cell with one or more synthetic RNA molecules, wherein the one or more synthetic RNA molecules include at least one RNA molecule encoding one or more reprogramming factors and wherein the transfecting results in the cell expressing the one or more reprogramming factors; and(d) repeating step (c) at least twice during 5 consecutive days, wherein the amount of one or more synthetic RNA molecules transfected in one or more later transfections is greater than the amount transfected in one or more earlier transfections, to result in the cell being reprogrammed to a less differentiated state,wherein steps (c) and (d) occur in the presence of a medium containing ingredients that support reprogramming of the differentiated cell to a less differentiated state.11. The method of claim 10 , wherein the differentiated cell is derived from a biopsy.12. The method of claim 10 , wherein the differentiated cell is from a human subject.13. The method of claim 11 , wherein the differentiated cell is derived from a dermal punch biopsy sample.14. The method of claim 10 , wherein the differentiated cell is a skin cell.15. The method of claim 10 , further comprising contacting the cell with at least one member of the group: poly-L-lysine claim 10 , poly-L-ornithine claim 10 , RGD peptide claim 10 , fibronectin claim 10 , vitronectin claim 10 , collagen claim 10 , and laminin.16. The method of claim 10 , wherein the synthetic RNA molecule contains at least one of a ...

Подробнее
17-08-2017 дата публикации

CULTURED MAMMALIAN LIMBAL STEM CELLS, METHODS FOR GENERATING THE SAME, AND USES THEREOF

Номер: US20170233698A1
Принадлежит:

The invention provides an isolated limbal stem or progenitor cell (LSC) population or LSC-like population comprising a chemically synthesized, recombinant or isolated nucleic acid encoding PAX6 integrated into a chromosome, or alternatively, not integrated remaining as an extrachromosomal genetic material, wherein the isolated LSC population is substantially free of non-LSC cells or wherein the LSC-like population is substantially free of non-LSC-like cells, or wherein the isolated LSC or LSC-like population is substantially free of non-LSC and non-LSC-like cells and uses thereof. 1. An isolated limbal stem or progenitor cell (LSC) population or LSC-like population comprising a chemically synthesized , recombinant or isolated nucleic acid encoding PAX6 integrated into a chromosome , or as an extrachromosomal genetic material , wherein the isolated LSC population is substantially free of non-LSC cells or wherein the LSC-like population is substantially free of non-LSC-like cells , or wherein the isolated LSC or LSC-like population is substantially free of non-LSC and non-LSC-like cells.2. The isolated LSC population or LSC-like population of claim 1 , wherein the chemically synthesized claim 1 , recombinant or isolated nucleic acid can express PAX6 or a fragment thereof claim 1 , wherein PAX6 or a fragment thereof can maintain LSC or LSC-like state or can direct a stem cell or progenitor cell to a LSC or LSC-like state claim 1 , and wherein LSC or LSC-like state restricts a cell population to a differentiation pathway resulting in corneal epithelial cells (CECs).3. The isolated LSC population or LSC-like population of claim 2 , wherein the chemically synthesized claim 2 , recombinant or isolated nucleic acid expresses PAX6 or a fragment thereof claim 2 , wherein PAX6 or a fragment thereof maintains LSC or LSC-like state or directs a stem cell or progenitor cell to a LSC or LSC-like state claim 2 , and wherein LSC or LSC-like state restricts a cell population to a ...

Подробнее
25-07-2019 дата публикации

METHODS AND PRODUCTS FOR TRANSFECTION

Номер: US20190225944A1
Принадлежит:

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed. 19.-. (canceled)10. A method for reprogramming a differentiated cell to a less differentiated state , comprising:(a) providing a differentiated cell;(b) culturing the differentiated cell; and wherein the one or more synthetic RNA molecules include at least one RNA molecule encoding one or more reprogramming factors;', 'wherein the transfecting results in the cell expressing the one or more reprogramming factors; and', 'wherein step (c) is performed at least twice and the amount of one or more synthetic RNA molecules transfected in one or more later transfections is greater than the amount transfected in one or more earlier transfections to result in the cell being reprogrammed to a less differentiated state and occurs in the presence of a medium containing ingredients that support reprogramming of the differentiated cell to a less differentiated state., '(c) transfecting the differentiated cell with one or more synthetic RNA molecules,'}11. The method of claim 10 , wherein the differentiated cell is derived from a biopsy.12. The method of claim 11 , wherein the differentiated cell is derived from a dermal punch biopsy sample.13. The method of claim 10 , wherein the differentiated cell is from a human subject.14. The method of claim 10 , wherein the differentiated cell is a skin cell.15. The method of claim 10 , further comprising contacting the cell with at least one member of the group: poly-L-lysine claim 10 , poly-L-ornithine claim 10 , RGD peptide claim 10 , fibronectin claim 10 , vitronectin claim 10 , collagen claim 10 , and laminin.16. The method of claim 10 , wherein the one or more synthetic RNA molecules contain at least one of a pseudouridine or a 5- ...

Подробнее
24-08-2017 дата публикации

PROCESS TO CREATE 3D TISSUE SCAFFOLD USING ELECTROSPUN NANOFIBER MATRIX AND PHOTOSENSITIVE HYDROGEL

Номер: US20170239388A1
Принадлежит:

A process providing a method to create 3D scaffolds using nano-scale fibers, comprising: deposition and alignment of a plurality of electrospun fiber layers on a substrate; application of a photosensitive biomedical polymer liquid to each fiber layer deposited on said substrate; deposition and cross-alignment of a plurality of electrospun fiber layers on said substrate; retaining said polymer liquid in place using said cross-aligned fiber layers; curing said polymer liquid on top of each fiber layer using UV light. 1. A process providing method to create 3D scaffolds using nano-scale fibers , comprising:deposition and alignment of a plurality of electrospun fiber in a first layer on a substrate;application of a photosensitive polymer liquid to said first fiber layer deposited on said substrate;deposition and cross-alignment of a plurality of electrospun fiber in a second layer on said substrate;retaining said polymer liquid in place using said cross-aligned fiber layers;curing said polymer liquid using ultra violet (UV) light.2. The method of claim 1 , wherein claim 1 , said substrate is adapted to produce a cylindrical 3D scaffold.3. The method of claim 1 , wherein claim 1 , said substrate is adapted to produce a 3D scaffold comprising at least two equal linear dimensions.4. A process providing a method for fabrication of a PCL electrospun nanofiber-PEGDA 3D scaffold claim 1 , comprising the steps of:depositing cross-aligned fibers on a substrate to produce a fiber matrix exhibiting a fiber-separation gap sufficient to prevent PEGDA gel from passing between the fibers in said fiber matrix;adjusting thickness of a PEGDA gel layer on said fiber matrix so that said PEGDA gel layer has uniform porosity;curing said PEGDA gel layer using ultraviolet light (UV) setting UV curing time to control and assure substantially uniform stiffness of said PEGDA gel layer;wherein, said steps are repeated to produce a plurality of fiber matrix and PEGDA layers, andwherein, the number ...

Подробнее
01-08-2019 дата публикации

Immortalization of Epithelial Cells and Methods of Use

Номер: US20190233798A1
Принадлежит:

The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing. 158-. (canceled)59. A method for continuously culturing non-keratinocyte epithelial (NKE) cells , comprising:a) culturing NKE cells isolated from tissue of a mammal, or cells derived therefrom, in a calcium-containing medium and in the presence of feeder cells or a medium conditioned with feeder cells; wherein the NKE cells are not embryonic stem cells, andb) inhibiting the activity of Rho kinase (ROCK) in the feeder cells, the NKE cells, or both during the culturing, thereby generating an expanded population of NKE cells.60. The method of claim 59 , wherein the NKE cells comprise adult stem cells.61. The method of claim 59 , wherein the NKE cells comprise cells from the gastrointestinal tract.62. The method of claim 60 , wherein the NKE cells comprise adult stem cells from the gastrointestinal tract.63. The method of claim 59 , wherein the NKE cells comprise large intestinal epithelial cells.64. The method of claim 59 , wherein the NKE cells comprise small intestinal epithelial cells.65. The method of claim 59 , wherein NKE cells comprise one or more cells selected from the group consisting of bronchial epithelial cells claim 59 , tracheal epithelial cells claim 59 , liver epithelial cells claim 59 , prostate epithelial cells claim 59 , pancreas epithelial cells claim 59 , pancreatic islet cells claim 59 , kidney epithelial cells claim 59 , bladder epithelial cells claim 59 , and ovarian epithelial cells.66. The method of claim 59 , wherein the expanded population of NKE cells comprises late passage NKE cells.67. The method of claim 59 , wherein the NKE cells are continuously cultured for at least 50 ...

Подробнее
23-07-2020 дата публикации

METHOD FOR SCREENING ANTI-AGING SUBSTANCES

Номер: US20200232972A1
Принадлежит: SHISEIDO COMPANY, LTD.

The purpose of the invention is to develop a method for screening anti-aging substances. The present inventors have found a phenomenon in which a dermis aging factor secreted by senescent cells acts on normal cells to promote the decomposition of dermal components and a reduction in the production of dermal components, and have arrived at developing a method for screening anti-aging substances by employing the dermis aging factor as an indicator. 1. A screening method for an anti-aging substance using the expression of a dermal senescence factor as an indicator.2. The screening method according to claim 1 , comprising the steps of:culturing a skin cell culture comprising a dermal fibroblast in a culture medium comprising a candidate drug;measuring expression of the dermal senescence factor in the culture; andselecting a candidate drug that can inhibit the expression of the dermal senescence factor.3. The screening method according to claim 2 , wherein the skin cell culture further comprises a stem cell.4. The screening method according to claim 1 , wherein the expression of the dermal senescence factor is determined by measuring the level of gene or protein expression of the dermal senescence factor.5. The screening method according to claim 1 , wherein the dermal senescence factor is IGFBP7 claim 1 , CFD claim 1 , or RSPO4.6Rosa multiflora. A dermal senescence factor expression inhibitor comprising a turmeric extract or a extract.7. The dermal senescence factor expression inhibitor according to claim 6 , wherein the dermal senescence factor is CFD.8. An aesthetic or non-therapeutic method of ameliorating wrinkles claim 6 , sagging claim 6 , or skin aging claim 6 , comprising inhibiting expression of a dermal senescence factor.9. The aesthetic or non-therapeutic method according to claim 8 , wherein the dermal senescence factor is IGFBP7 claim 8 , CFD claim 8 , or RSPO4.10. The screening method according to claim 2 , wherein the expression of the dermal senescence ...

Подробнее
21-10-2021 дата публикации

Methods for Development and Use of Minimally Polarized Function Cell Micro-Aggregate Units in Tissue Applications Using LGR4, LGR5 and LGR6 Expressing Epithelial Stem Cells

Номер: US20210322643A1
Автор: Lough Denver M.
Принадлежит:

Provided herein are constructs of micro-aggregate multicellular, minimally polarized grafts containing Leucine-rich repeat-containing G-protein coupled Receptor (LGR) expressing cells for wound therapy applications, tissue engineering, cell therapy applications, regenerative medicine applications, medical/therapeutic applications, tissue healing applications, immune therapy applications, and tissue transplant therapy applications which preferably are associated with a delivery vector/substrate/support/scaffold for direct application. 137.-. (canceled)38. A composition , comprising a cryoprotectant; anda tissue section comprising a dermal segment, an epidermal segment, and a segment of a follicular unit of a mammalian cutaneous tissue specimen, whereinthe dermal segment and the epidermal segment are outside the follicular unit;the segments are interconnected;the segment of the follicular unit comprises living LGR-expressing stem cells that are exposed; andthe composition is capable of regenerating functional tissue comprising epidermis, dermis, and appendages when transplanted to a damaged tissue site in a subject in need thereof.39. The composition of claim 38 , further comprising a second tissue section comprising a second dermal segment and a second epidermal segment claim 38 , wherein the second dermal segment and the second epidermal segment are outside the follicular unit and the second dermal segment and second epidermal segment are interconnected.40. The composition of claim 38 , wherein the mammalian cutaneous tissue specimen is a human cutaneous tissue specimen.41. The composition of claim 38 , wherein the cryoprotectant comprises dimethylsulfoxide.42. The composition of claim 38 , further comprising a cell sustaining media.43. The composition of claim 42 , wherein the cell sustaining media comprises pulse rescue media.44. The composition of claim 38 , further comprising one or more supplements selected from growth factors claim 38 , LGR specific binding ...

Подробнее
04-12-2014 дата публикации

Nail stem cells and methods of use thereof

Номер: US20140356333A1
Автор: Makoto Takeo, Mayumi Ito
Принадлежит: New York University NYU

The present invention is directed to an in vitro method for promoting proliferation, survival, and/or differentiation of K14+, K17+ nail stem cells (NSCs). The instant methods may be used to generate an expanded population of K14+, K17+ NSCs in vitro and expanded NSC populations in which a Wnt pathway is activated are envisioned as therapeutic agents. Methods for screening to identify agents capable of modulating K14+, K17+ NSC proliferation, survival, and/or differentiation are also encompassed herein, as are isolated, pure populations of homogeneous K14+, K17+ NSCs.

Подробнее
22-08-2019 дата публикации

Decellularized Biomaterial from Non-Mammalian Tissue

Номер: US20190255217A1
Автор: Ryanne EARLY

The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and non-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, duration and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue.

Подробнее
21-09-2017 дата публикации

METHODS AND PRODUCTS FOR TRANSFECTION

Номер: US20170267979A1
Принадлежит:

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

Подробнее
13-08-2020 дата публикации

METHOD FOR THE IN VITRO PREPARATION OF DERMAL PAPILLA AND HAIR FOLLICLE EQUIVALENTS

Номер: US20200255801A1
Принадлежит:

The invention relates to a process for the in vitro preparation of a dermal papilla equivalent from fibroblasts derived from the dermal papilla and/or from the connective tissue sheath; to a process for the in vitro preparation of a hair follicle equivalent by culturing proliferative epithelial cells on said dermal papillae thus obtained; to the in vitro dermal papilla and hair follicle equivalents produced by means of the abovementioned processes, and to the uses thereof for treating alopecia and for evaluating the effect of cosmetic, pharmaceutical or dermatological products. 1. A process for the in vitro preparation of a dermal papilla equivalent , comprising at least one step of culturing fibroblasts derived from the dermal papilla and/or from the connective tissue sheath on a support comprising a serum-free nutritive culture medium B for a period of time that is sufficient to allow said fibroblasts to detach from said support and to group together to form at least one spheroid; the surface of said support used not permitting cell adhesion; said culture support is chosen from 2D or 3D round-bottomed microplate culture supports.2. The process as claimed in claim 1 , in which said fibroblasts are seeded on said 2D culture support at a density of at least 14 000 cells/cm.3. The process as claimed in claim 1 , in which said fibroblasts are seeded on said 3D culture support at a density of at least 3000 cells/cm.4. The process as claimed in claim 1 , in which said nutritive culture medium B comprises from 500 to 1500 mg/l of amino acids claim 1 , from 2 to 18 mg/l of vitamins claim 1 , from 1500 to 4500 mg/l of glucose claim 1 , from 8750 to 10 000 mg/l of inorganic salts claim 1 , from 2 to 20 μg/ml of insulin claim 1 , from 2 to 60 ng/ml of hydrocortisone claim 1 , and optionally from 50 to 200 μg/ml of antibiotics and/or of antimycotics.5. The process as claimed in claim 1 , in which said fibroblasts are cultured for at least 3 days.6. The process as claimed in ...

Подробнее
11-12-2014 дата публикации

METHOD FOR PREPARING INDUCED PARAXIAL MESODERM PROGENITOR (IPAM) CELLS AND THEIR USE

Номер: US20140363886A1
Принадлежит:

The present invention relates to an ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells, said method comprising the step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of the Wnt signaling pathway and an effective amount of an inhibitor of the Bone Morphogenetic Protein (BMP) signaling pathway. 1. An ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells , said method comprising a step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of a Wnt signaling pathway.2. An ex vivo method for preparing induced paraxial mesoderm progenitor (iPAM) cells , said method comprising a step of culturing pluripotent cells in an appropriate culture medium comprising an effective amount of an activator of a Wnt signaling pathway and an effective amount of an inhibitor of a Bone Morpho genetic Protein (BMP) signaling pathway.3. The ex vivo method according to claim 1 , wherein said Wnt signaling pathway is a canonical Wnt/beta catenin signaling pathway and/or a Wnt/PCP signaling pathway.4. The ex vivo method according to claim 1 , wherein the activator of said Wnt signaling pathway is a member of an R-spondin family.5. The ex vivo method according to claim 4 , wherein said member of the R-spondin family is selected from the group consisting of R-spondin 3 claim 4 , R-spondin2 claim 4 , and a combination of said R-spondin 3 and R-spondin 2.6. The ex vivo method according to claim 5 , wherein said R-spondin-3 is a human R-spondin-3 of sequence SEQ ID NO 1 or a human R-spondin-3 isoform 2 of sequence SEQ ID NO 5.7. The ex vivo method according to claim 5 , wherein said R-spondin-2 is a human R-spondin-2 of sequence SEQ ID No 3 claim 5 , a human R-spondin-2 isoform 2 of sequence SEQ ID NO 6 claim 5 , or a human R-spondin-2 isoform 3 of sequence SEQ ID NO 7.8. The ex vivo method according to claim 2 , wherein said ...

Подробнее
29-09-2016 дата публикации

Methods and products for transfection

Номер: US20160281059A1
Принадлежит: Factor Bioscience Inc

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

Подробнее
03-09-2020 дата публикации

THERAPEUTIC USES OF FLAP OF GENETICALLY MODIFIED CELLS

Номер: US20200276246A1
Принадлежит: HOLOSTEM TERAPIE AVANZATE S.R.L.

The present invention refers to a flap of genetically modified cells on fibrin substrate for use in the treatment of Epidermolysis Bullosa (EB) and/or for use in a method to promote in vivo cell adhesion and/or in vivo cell growth and/or cell regeneration and/or for use in a surgical method, preferably for use in the repair or replacement of living tissue, in an EB patient. 1. A method for the treatment of Epidermolysis Bullosa (EB) comprising administering to a subject in need thereof a flap of genetically modified cells on a fibrin substrate , wherein said genetically modified cells are genetically modified with at least one heterologous nucleic acid comprising a nucleotide sequence encoding:a) at least one chain selected from the group consisting of: β3, α3 and γ2 chain of laminin-332, and/orb) collagen XVII and/orc) at least one α6β4 integrin and/ord) collagen VII and/ore) keratin 5 and/or Keratin 14 and/orf) Plectin.2. A The method of claim 1 , wherein the treatment promotes in vivo cell adhesion and/or in vivo cell growth and/or cell regeneration optionally in the repair or replacement of living tissue claim 1 , in an EB patient.3. The method according to claim 1 , wherein the EB is Junctional Epidermolysis Bullosa (JEB).4. The method according to claim 3 , wherein the heterologous nucleic acid comprises a nucleotide sequence encoding laminin-332 β3 chain and/or collagen XVII.5. The method according to claim 1 , wherein:a) the laminin-332 β3 chain comprises an amino acid sequence having at least 75% amino acid sequence identity to the amino acid sequence SEQ ID NO: 6 and/orb) the collagen XVII comprises an amino acid sequence having at least 75% amino acid sequence identity to the amino acid sequence SEQ ID NO:4 and/orc) the collagen VII comprises an amino acid sequence having at least 75% amino acid sequence identity to the amino acid sequence SEQ ID NO: 2.6. The method according to claim 1 , wherein said heterologous nucleic acid further comprises a promoter ...

Подробнее
10-09-2020 дата публикации

ENGINEERING MESODERMAL PRECURSOR CELL COMPOSITIONS FOR THE TREATMENT OR PROPHYLAXIS OF PERFUSION DISORDERS

Номер: US20200281986A1
Автор: Yoder Mervin C.
Принадлежит: VASCUGEN, INC.

The present disclosure describes the engineering of a mesodermal precursor cell population obtained through the differentiation of induced pluripotent stem cells (iPSCs) for the cell therapy treatment of perfusion disorders. The modifications improve the survival and clonal proliferation of the mesodermal precursor cell population ex vivo and facilitate their migration to sites of ischemic injury in vivo. 1. An isolated population of engineered mesodermal precursor cells expressing at least one of KDR , NCAM and APLNR , wherein the precursor cells are engineered to enhance the non-neoplastic proliferation and survival of the mesodermal precursor cells and/or the migration of the mesodermal precursor cells and their progeny toward ischemic tissue.2. The population of engineered mesodermal precursor cells of claim 1 , wherein the mesodermal precursor cells express at least two of KDR claim 1 , NCAM and APLNR.3. The population of engineered mesodermal precursor cells of claim 1 , wherein the mesodermal precursor cells express KDR claim 1 , NCAM and APLNR.4. The population of engineered mesodermal precursor cells of any claim 1 , wherein the mesodermal precursor cells can differentiate into endothelial progenitor cells.5. The population of engineered mesodermal precursor cells of any claim 4 , wherein the endothelial progenitor cells comprise endothelial colony forming-like cells (ECFC-like).6. The population of engineered mesodermal precursor cells of claim 1 , wherein the mesodermal precursor cells are engineered by gene editing.7. The population of engineered mesodermal precursor cells of claim 1 , wherein the mesodermal precursor cells comprise an agent claim 1 , wherein the agent enhances the non-neoplastic proliferation and survival of the mesodermal precursor cells and/or the migration of the mesodermal precursor cells and their progeny toward ischemic tissue.8. The population of engineered mesodermal precursor cells of claim 7 , wherein the agent comprises a ...

Подробнее
26-10-2017 дата публикации

ENGINEERED SKIN EQUIVALENT, METHOD OF MANUFACTURE THEREOF AND PRODUCTS DERIVED THEREFROM

Номер: US20170306428A1
Принадлежит:

Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same. 1198.-. (canceled)199. A method of making a synthetic leather comprising:(a) forming an artificial dermal layer comprising a fibroblast; and(b) tanning at least a portion of said artificial dermal layer, thereby forming said synthetic leather, wherein said fibroblast is differentiated from an induced pluripotent stem cell.200. The method of claim 199 , further comprising forming an artificial epidermal layer.201. The method of claim 200 , wherein said artificial epidermal layer comprises a keratinocyte.202. The method of claim 201 , further comprising placing said artificial epidermal layer upon said artificial dermal layer thereby forming a layered structure.203. The method of claim 201 , wherein said keratinocyte is differentiated from an induced pluripotent stem cell.204. The method of claim 202 , wherein said layered structure further comprises a melanocyte.205. The method of claim 204 , wherein said melanocyte is differentiated from an induced pluripotent stem cell.206. The method of claim 202 , wherein said artificial epidermal layer claim 202 , said layered structure or said artificial dermal layer further comprises collagen.207. The method of claim 206 , wherein said collagen is produced at least in part by a collagen producing cell claim 206 , is separately added claim 206 , or any combination thereof.208. The method of claim 199 , wherein said synthetic leather further comprises one or more of keratin claim 199 , elastin claim 199 , gelatin claim 199 , proteoglycan claim 199 , dermatan sulfate proteoglycan claim 199 , glycosoaminoglycan claim 199 , fibronectin claim 199 , laminin claim 199 , dermatopontin claim 199 , lipid claim 199 , fatty acid claim 199 , carbohydrate claim 199 , or a combination thereof.209. The method of claim 199 , wherein a thickness of said artificial ...

Подробнее
25-10-2018 дата публикации

Polypeptides and Antibodies to Treat Skin Conditions Associated with Overproduction of Sebum

Номер: US20180305419A1
Принадлежит:

The present application provides compositions, methods, and uses of polypeptide or antibody inhibitors of insig-1 ubiquitination for preventing or treating skin diseases or conditions associated with overproduction of sebum, such as acne and seborrhea. 1. A composition for use to treat a skin disease or condition associated with overproduction of sebum , said composition comprising a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO: 21 or a conservatively substituted amino acid sequence of SEQ ID NO: 21 that retains the lysine residues at amino acid positions 2 and 4 of SEQ ID NO: 21 and a pharmaceutically or cosmetically acceptable carrier.2. The composition of claim 1 , wherein the polypeptide further comprises a linker.3. The composition of claim 1 , wherein the composition further comprises a cell penetrating peptide or skin penetrating peptide joined to the polypeptide.4. (canceled)5. (canceled)6. A composition of claim 1 , wherein the polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 21.7. (canceled)8. The composition of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2 or having at least 90% sequence identity to a conservatively substituted amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.9. The composition of claim 1 , wherein the polypeptide comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 2 or having at least 95% sequence identity to a conservatively substituted amino acid sequence of SEQ ID NO:2.10. The composition of claim 1 , wherein the polypeptide comprises an amino acid sequence having an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 with a single non-conservative amino acid substitution claim 1 , deletion claim 1 , or insertion or having a conservatively substituted amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 with a single non-conservative amino acid substitution claim ...

Подробнее
02-11-2017 дата публикации

SERUM-FREE MEDIUM CONTAINING PDGF FOR DS CELLS

Номер: US20170313982A1
Принадлежит: SHISEIDO COMPANY, LTD.

The problem to be solved by the present invention is to provide a serum-free medium suitable for culturing of DS cells. The present invention relates to a serum-free medium for culturing of DS cells containing platelet-derived growth factor (PDGF), or to a method for culturing of dermal sheath (DS) cells, using serum-free medium comprising PDGF. 16.-. (canceled)7. A method for culturing dermal sheath (DS) cells , comprising culturing DS cells in a serum-free medium comprising platelet-derived growth factor (PDGF) , wherein the PDGF is PDGF-BB.8. The method of claim 7 , wherein the dermal sheath (DS) cells are derived from the dermal sheath cup (DSC) region.9. The method of claim 7 , wherein a basal medium of the serum-free medium is selected from the group consisting of HFDM-1(+) (Cell Science & Technology Institute) claim 7 , HFDM-1(−) (Cell Science & Technology Institute) claim 7 , StemPro MSC SFM CTS (sup+) (Life Technologies) claim 7 , StemPro MSC SFM CTS (sup−) (Life Technologies) and Mosaic hMSC SF Culture Medium (sup+) (BD).10. The method of claim 7 , wherein the amount of PDGF is about 0.01 ng/mL to 10 μg/mL.11. The method of claim 7 , wherein the serum free-medium further comprises a Wnt signal activating agent.12. The method of claim 11 , wherein the Wnt signal activating agent is an exhibiting glycogen synthase kinase-3 (GSK-3) inhibitor activity agent.13. The method of claim 11 , wherein the amount of Wnt signal activating agent is about 0.01 μM to 100 μM.14. The method of claim 7 , wherein the DS cells are cultured in a manner to form a sphere. The present invention relates to a serum-free medium for culturing of DS cells, comprising platelet-derived growth factor (PDGF), and to a method for culturing of dermal sheath (DS) cells, using serum-free medium comprising PDGF.Hair is considered very important for aesthetic outer appearance. Therefore, alopecia or hair loss due to congenital or acquired causes can be seriously distressing for individuals. ...

Подробнее
17-11-2016 дата публикации

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VITILIGO

Номер: US20160331787A1
Автор: Xu Xiaowei, Yu Hong
Принадлежит:

Compositions and methods for darkening skin and treating vitiligo are provided. 1. An isolated hair follicle derived melanoblast.2. A composition comprising the hair follicle derived melanoblasts of and at least one pharmaceutically acceptable carrier.3. The composition of further comprising hair follicle derived melanocytes.4. A method of treating vitiligo claim 2 , said method comprising administering to a patient in need thereof the composition of .5. A method of darkening skin claim 2 , said method comprising administering to a patient in need thereof the composition of .6. A method of producing the hair follicle derived melanoblast of claim 1 , said method comprising:a) obtaining hair follicles from a patient;b) culturing the cells of the hair follicle obtained in step a) in medium void of cholera toxin and 12-O-tetradecanoylphorbol-13-acetate; andc) optionally isolating the generated melanoblasts.7. The method of claim 6 , wherein the medium of step b) comprises endothelin-3 claim 6 , stem cell factor claim 6 , and basic fibroblast growth factor. This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 61/101,388, filed on Sep. 30, 2008. The foregoing application is incorporated by reference herein.The present invention relates to the fields of skin pigmentation and vitiligo therapies. Specifically, methods and compositions for darkening skin and the treatment of vitiligo are provided.Several publications and patent documents are cited throughout the specification in order to describe the state of the art to which this invention pertains. Each of these citations is incorporated herein by reference as though set forth in full.Vitiligo is a skin condition resulting from loss of melanocytes in the skin. Autoimmunity has been proposed as a cause for this disease. As a result of the loss of melanocytes, white patches of skin appear on different parts of the body. Any part of the body may be affected, although hair color is ...

Подробнее
08-11-2018 дата публикации

ABCB5 POSITIVE MESENCHYMAL STEM CELLS AS IMMUNOMODULATORS

Номер: US20180320131A1
Автор: Frank Markus H.
Принадлежит:

The present invention is directed to purified preparations of dermal mesenchymal stem cells that are characterized by the cell surface expression of the ABCB5 P-glycoprotein. The cells may be used for any purpose that mesenchymal stem cells from other course are used. For instance they may be administered to treat an organ transplant recipient to improve allograft survival or as a treatment to patients with autoimmune diseases such as multiple sclerosis and rheumatoid arthritis. 1. A method for inducing tissue generation , comprising promoting differentiation of an isolated preparation of ABCB5 positive dermal mesenchymal stem cells , wherein ABCB5 positive dermal cells comprise at least 95% of the isolated preparation of ABCB5 positive dermal mesenchymal stem cells.2. The method of claim 1 , wherein the isolated preparation of ABCB5 positive dermal mesenchymal stem cells are first grown in an undifferentiated state through mitotic expansion.3. The method of claim 1 , wherein the isolated preparation of ABCB5 positive dermal mesenchymal stem cells are harvested and activated to differentiate into bone claim 1 , cartilage claim 1 , ligament claim 1 , tendon claim 1 , stroma claim 1 , muscle and adipose tissue.4. The method of claim 1 , wherein the isolated preparation of ABCB5 positive dermal mesenchymal stem cells are seeded onto a matrix or scaffold.5. The method of claim 4 , wherein the matrix is a polymeric mesh or sponge.6. The method of claim 4 , wherein the matrix is a polymeric hydrogel.7. The method of claim 1 , wherein the ABCB5 positive dermal mesenchymal stem cells are injected into a soft or hard tissue defect.8. The method of claim 7 , wherein the tissue defect is a trauma or burn.9. A matrix seeded with a population of dermal stem cells claim 7 , wherein at least 95% of the population of dermal stem cells are ABCB5+ dermal mesenchymal stem cells.10. The matrix of claim 9 , wherein the matrix is shaped to fill a tissue defect.11. The matrix of claim 9 , ...

Подробнее
08-10-2020 дата публикации

CELL CULTURE METHOD AND CELL CULTURE APPARATUS

Номер: US20200318057A1
Принадлежит: TOYO SEIKAN GROUP HOLDINGS, LTD.

A cell culture apparatus for conducting cell culture in which a culture medium is supplied together with cells to a container formed of a flexible material, wherein, a base having a flat mounting surface that holds the container is provided, partition pieces that can be protruded from the mounting surface for a prescribed height are embedded in the base, and when the partition pieces are accommodated into the base, upper end surfaces of the partition pieces are flushed with the mounting surface. 1. A cell culture apparatus for conducting cell culture in which a culture medium is supplied together with cells to a container formed of a flexible material , wherein ,a base having a flat mounting surface that holds the container is provided,partition pieces that can be protruded from the mounting surface for a prescribed height are embedded in the base, andwhen the partition pieces are accommodated into the base, upper end surfaces of the partition pieces are flushed with the mounting surface.2. The cell culture apparatus according to claim 1 , wherein the base is provided with a holding member that forms the mounting surface and a partition plate on which a plurality of the partition pieces are arranged in parallel with each other with a prescribed interval.3. The cell culture apparatus according to claim 1 , wherein the base is pivotably supported at one end thereof by a supporting frame such that it can be rotatably moved and due to the rotational operation of the base claim 1 , after the container is moved to a position higher than the initial position claim 1 , the container is returned to an initial position by rotatably moving the base as if it falls down and vibration that is due to an impact generated by receiving of the base by the supporting frame is applied to the container returned to the initial position claim 1 , thereby to stir a content liquid in the container.4. The cell culture apparatus according to claim 1 , wherein the pressing plate for ...

Подробнее
03-12-2015 дата публикации

DETERGENT TREATED BIOLOGICAL TISSUE WITH LOW RESIDUAL DETERGENT AND METHOD OF PRODUCING THE SAME

Номер: US20150344843A1
Автор: Schallenberger Mark
Принадлежит:

This invention relates to a detergent treated biological tissue with low residual detergent and methods of making the same. The low residual detergent is a clinically beneficial aspect of the biological tissue. 1. A detergent treated biological tissue with low levels of residual detergent wherein the concentration of residual detergent in the detergent treated biological tissue is less than about 200 ng of detergent per mg of tissue.2. The biological tissue of claim 1 , wherein the detergent treated biological tissue is partially decellularized.3. The biological tissue of claim 1 , wherein the detergent treated biological tissue is completely decellularized.4. The biological tissue of claim 1 , wherein the detergent is selected from the group consisting of anionic surfactants claim 1 , cationic surfactants claim 1 , nonionic surfactants and combinations thereof.5. The biological tissue of claim 1 , wherein the detergent is sodium dodecyl sulfate.6. The biological tissue of claim 1 , wherein the detergent is Triton™ X-100 ((CHO)CHO).7. The biological tissue of claim 1 , wherein the biological tissue is selected from the group consisting of allograft tissue claim 1 , autograft tissue and xenograft tissue.8. The biological tissue of claim 1 , wherein the biological tissue is selected from the group consisting of cortical bone claim 1 , cancellous bone claim 1 , demineralized bone claim 1 , connective tissue claim 1 , tendon claim 1 , pericardium claim 1 , dermis claim 1 , cornea claim 1 , dura mater claim 1 , fascia claim 1 , heart valve claim 1 , ligament claim 1 , capsular graft claim 1 , cartilage claim 1 , collagen claim 1 , nerve claim 1 , placental tissue claim 1 , and combinations thereof.9. The biological tissue of claim 1 , wherein the biological tissue is human dermis.10. A method of preparing a low residual detergent biological tissue claim 1 , comprising:exposing a biological tissue to a detergent containing solution to produce a treated tissue; andexposing ...

Подробнее
15-11-2018 дата публикации

METHODS AND PRODUCTS FOR TRANSFECTION

Номер: US20180327720A1
Принадлежит:

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed. 1. A method for reprogramming a cell , comprising:a. contacting a cell with a medium containing albumin, wherein the albumin is treated with an ion-exchange resin or charcoal,b. contacting the cell with one or more synthetic RNA molecules, wherein the one or more synthetic RNA molecules includes at least one RNA molecule encoding Oct4 protein, andc. repeating step (b) at least twice during 5 consecutive days.2. The method of claim 1 , wherein the albumin was treated with a short-chain fatty acid.3. The method of claim 2 , wherein the albumin was brought to a temperature of at least 40 C.4. The method of claim 1 , wherein the one or more synthetic RNA molecules further includes at least one RNA molecule encoding at least one member of the group: Sox2 protein claim 1 , Klf4 protein claim 1 , and c-Myc protein.5. The method of claim 1 , wherein the one or more synthetic RNA molecules further includes at least one RNA molecule encoding Sox2 protein claim 1 , at least one RNA molecule encoding Klf4 protein claim 1 , and at least one RNA molecule encoding c-Myc protein.6. The method of claim 1 , further comprising contacting the cell with at least one member of the group: poly-L-lysine claim 1 , poly-L-ornithine claim 1 , RGD peptide claim 1 , fibronectin claim 1 , vitronectin claim 1 , collagen claim 1 , and laminin claim 1 , or a biologically active fragment claim 1 , functional variant or family-member thereof.7. The method of claim 1 , wherein the one or more synthetic RNA molecules contains at least one member of the group: a pseudouridine residue and a 5-methylcytidine residue.8. The method of claim 7 , wherein the cell is a skin cell claim 7 , and the method further ...

Подробнее
30-11-2017 дата публикации

Extracellular Matrix Scaffolds

Номер: US20170342374A1
Принадлежит:

A method for micro-tissue encapsulation of cells includes coating a tissue scaffold stamp with an extracellular matrix compound; depositing the tissue scaffold stamp onto a thermoresponsive substrate; seeding the tissue scaffold stamp with a cell culture; incubating the cell culture on the tissue scaffold stamp at a temperature that is specified, wherein the cell culture forms a cell patch that is attached to the extracellular matrix compound; removing the thermoresponsive substrate by lowering the temperature; removing the tissue scaffold stamp from the cell patch to form a micro-tissue structure by dissolving the tissue scaffold stamp in a solvent; folding the micro-tissue structure by suspending the micro-tissue in the solvent to enable the cell patch to fold the micro-tissue structure; collecting the folded micro-tissue structure from the solvent; and administering the folded micro-tissue structure to an organism. 1. A method for micro-tissue encapsulation of cells comprising:coating a tissue scaffold stamp with an extracellular matrix compound;depositing the tissue scaffold stamp onto a thermoresponsive substrate;seeding the tissue scaffold stamp with a cell culture;incubating the cell culture on the tissue scaffold stamp at a temperature that is specified, wherein the cell culture forms a cell patch that is attached to the extracellular matrix compound;removing the thermoresponsive substrate by lowering the temperature;removing the tissue scaffold stamp from the cell patch to form a micro-tissue structure by dissolving the tissue scaffold stamp in a solvent;folding the micro-tissue structure by suspending the micro-tissue in the solvent to enable the cell patch to fold the micro-tissue structure;collecting the folded micro-tissue structure from the solvent; andadministering the folded micro-tissue structure to an organism.2. The method of claim 1 , wherein administering the micro-tissue structure to an organism comprises injecting the micro-tissue structure.3. ...

Подробнее
24-12-2015 дата публикации

Method of detaching adherent cells for flow cytometry

Номер: US20150368620A1
Автор: Luke E. Esau, Mandeep KAUR

In one aspect, a method for detaching adherent cells can include adding a cell lifting solution to the media including a sample of adherent cells and incubating the sample of adherent cells with the cell lifting solution. No scraping or pipetting is needed to facilitate cell detachment. The method do not require inactivation of cell lifting solution and no washing of detaching cells is required to remove cell lifting solution. Detached cells can be stained with dye in the presence of cell lifting solution and are further analyzed using flow cytometer. The method has been tested using 6 different cell lines, 4 different assays, two different plate formats (96 and 384 well plates) and two different flow cytometry instruments. The method is simple to perform, less time consuming, with no cell loss and makes high throughput flow cytometry on adherent cells a reality.

Подробнее
21-12-2017 дата публикации

CELL CULTURE METHOD AND CELL CULTURE APPARATUS

Номер: US20170362559A1
Принадлежит: TOYO SEIKAN GROUP HOLDINGS, LTD.

A bottom surface of a container () formed of a flexible material is partially raised to be partitioned it into plural compartments (), and cells are cultured in each compartment (). In due time, the compartments () are removed to expand a culture area in the container. As a result, the cell density at the time of culture can be maintained at an appropriate level, and an operation of transferring cells from one culture container to another culture container at the time of proliferating cells in a large amount can be eliminated, whereby damage on cells and risk of contamination can be reduced. 1. A method of culturing cells in which a culture medium is supplied together with cells to a container formed of a flexible material , thereby to conduct cell culture , wherein ,a bottom surface of the container is partially raised to be partitioned into a plurality of compartments,the cells are cultured in each compartment, andin due time, the compartments are removed to expand a culture area in the container.2. The method of culturing cells according to claim 1 , wherein the container is held on a base having a flat mounting surface and in which partition pieces that can be protruded from the mounting surface for a prescribed height are embedded claim 1 , andthe bottom surface of the container is partially raised by partition pieces protruding from the mounting surface, thereby to partition the bottom surface into a plurality of compartments.3. The method of culturing cells according to claim 2 , wherein the partition pieces are accommodated into the base claim 2 , and the upper end surfaces of the partition pieces are flushed with the mounting surface claim 2 , thereby to remove the compartments.4. The method of culturing cells according to claim 1 , wherein claim 1 ,when cell culture is continued by expanding the culture area in the container by removing the compartments,after moving the container to a position higher than an initial position, the container is returned to ...

Подробнее
05-12-2019 дата публикации

ENGINEERED SKIN EQUIVALENT, METHOD OF MANUFACTURE THEREOF AND PRODUCTS DERIVED THEREFROM

Номер: US20190367732A1
Принадлежит:

Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same. 1198.-. (canceled)199. A method comprising: tanning at least a portion of an artificial dermal layer comprising a hair follicle cell , wherein said dermal layer comprises a fibroblast differentiated from a stem cell.200. The method of claim 199 , wherein said stem cell is an induced pluripotent stem cell.201. The method of claim 199 , wherein said stem cell is an embryonic stem cell.202. The method of claim 199 , wherein said stem cell is a totipotent stem cell.203. The method of claim 199 , wherein said artificial dermal layer further comprises a pigment.204. The method of claim 199 , wherein said fibroblast expresses CD10 claim 199 , CD73 claim 199 , CD44 claim 199 , CD90 claim 199 , type I collagen claim 199 , type III collagen claim 199 , prolyl-4-hydroxylase beta claim 199 , or a combination thereof.205. The method of claim 199 , wherein said artificial dermal layer comprises collagen.206. The method of claim 205 , wherein said dermal layer is subjected to further processing.207. The method of claim 206 , wherein said processing is selected from a group consisting of preserving claim 206 , soaking claim 206 , bating claim 206 , pickling claim 206 , depickling claim 206 , thinning claim 206 , retanning claim 206 , lubricating claim 206 , crusting claim 206 , wetting claim 206 , sammying claim 206 , shaving claim 206 , rechroming claim 206 , neutralizing claim 206 , dyeing claim 206 , fatliquoring claim 206 , filling claim 206 , stripping claim 206 , stuffing claim 206 , whitening claim 206 , fixating claim 206 , setting claim 206 , drying claim 206 , conditioning claim 206 , milling claim 206 , staking claim 206 , buffing claim 206 , finishing claim 206 , oiling claim 206 , brushing claim 206 , padding claim 206 , impregnating claim 206 , spraying claim 206 , roller coating claim 206 , ...

Подробнее
17-12-2020 дата публикации

A process of preparing buccal epithelial cell suspension and its use

Номер: US20200392465A1
Принадлежит: Regrow Biosciences Pvt Ltd

A process of preparing buccal epithelial cell suspension and cystoscopically implanting the cell suspension in the defect site of the adult human urethra.

Подробнее
03-11-2022 дата публикации

METHOD OF PRODUCING SKIN-DERIVED PRECURSOR CELLS

Номер: US20220348868A1
Автор: NAKAGIRI Yoriko
Принадлежит: KAO CORPORATION

A method of producing skin-derived precursor cells, comprising culturing human-derived pluripotent stem cells in a differentiation-inducing medium containing an agonist of Wnt signaling to differentiate the pluripotent stem cells into skin-derived precursor cells:, a differentiation-inducing medium for differentiating human-derived pluripotent stem cells into skin-derived precursor cells, comprising an agonist of Wm signaling as a differentiation-inducing promoter; and a differentiation-inducing promoter for differentiating human-derived pluripotent stem cells into skin-derived precursor cells, comprising an agonist of Wnt signaling as an active ingredient. 18-. (canceled)9. A method of differentiating human-derived pluripotent stem cells into skin-derived precursor cells , the method comprising:differentiating human-derived pluripotent stern cells into skin-derived precursor cells in a medium,wherein the medium comprises an agonist of Wnt signaling as a differentiation-inducing promoter.10. The method according to claim 9 , wherein the pluripotent stern cells are induced pluripotent stern cells.11. The method according to claim 9 , wherein the human-derived pluripotent stem cells are neural crest stern cells derived from pluripotent stem cells.12. The method according to claim 9 , wherein skin-derived precursor cells differentiated using the differentiation-inducing medium are passage-cultured at least one time.13. The method according to claim 9 , wherein a basal medium of the medium is a D-MEM/Ham's F12 medium.14. The method according to claim 9 , wherein the medium further comprises a B-27 supplement claim 9 , and at least one nutritional factor selected from the group consisting of a epidermal growth factor and a basic fibroblast growth factor.15. The method according to claim 9 , wherein the agonist of Wnt signaling is at least one selected from the group consisting of an aminopyrimidine compound claim 9 , a bis-indolo(indirubin) compound claim 9 , an ...

Подробнее
22-12-2022 дата публикации

ENGINEERED SKIN EQUIVALENT, METHOD OF MANUFACTURE THEREOF AND PRODUCTS DERIVED THEREFROM

Номер: US20220403172A1
Принадлежит:

Disclosed herein are synthetic leathers, artificial epidermal layers, artificial dermal layers, layered structures, products produced therefrom and methods of producing the same. 1198.-. (canceled)199. A method of forming a tanned leather , wherein said method comprises: i) wherein said scaffold comprises a polycaprolactone, a polyethylene, a polypropylene, a polyvinyl alcohol, a zein, an alginate, a starch, a cellulose, a cotton, an acetate, an acrylic, a fiber, a linen, a nylon, a rayon, a velvet, a modacrylic, an olefin polyester, a saran, a vinyon, a wool, a jute, a hemp, a bamboo, a flax, or any combination thereof, and', 'ii) wherein said cell layer comprises a collagen; and, 'a) forming a cell layer comprising an immortalized cell in contact with a scaffold,'}b) tanning at least a portion of said collagen to generate said tanned leather.200. The method of claim 199 , wherein said scaffold comprises a fiber.201. The method of claim 200 , wherein said fiber comprises a latex claim 200 , a vegetable claim 200 , a polyamide claim 200 , a modified cellulose claim 200 , or any combination thereof.202. The method of claim 199 , wherein said scaffold comprises said cellulose claim 199 , wherein said cellulose comprises a rayon claim 199 , a viscose claim 199 , an acetate claim 199 , a rayon acetate claim 199 , or any combination thereof.203. The method of claim 199 , further comprising forming said tanned leather into one or more of a watch strap claim 199 , a belt claim 199 , a packaging claim 199 , a shoe claim 199 , a boot claim 199 , a footwear claim 199 , a glove claim 199 , a clothing claim 199 , a luggage claim 199 , a bag claim 199 , a clutch claim 199 , a purse claim 199 , a backpack claim 199 , a wallet claim 199 , a saddle claim 199 , a harness claim 199 , a whip claim 199 , or any combination thereof.204. The method of claim 199 , wherein said scaffold comprises said bamboo.205. The method of claim 199 , wherein said scaffold comprises said polyethylene ...

Подробнее
08-09-2017 дата публикации

培养基、细胞培养用试剂盒及细胞培养方法

Номер: CN107142237A
Автор: 李晖
Принадлежит: 李晖

本发明涉及培养基、细胞培养用试剂盒及细胞培养方法,特别是用于上皮细胞培养的培养基、细胞培养用试剂盒及细胞培养方法。所述培养基包含血清、钙成分和ROCK抑制剂。

Подробнее
15-10-2018 дата публикации

3 Dimensional cell sheet for treating wound and ulcer and preparing the same

Номер: KR101908030B1
Автор: 노종렬

The present invention relates to a three-dimensional cell sheet for wound or ulcer treatment and a method of manufacturing the same. The cell sheet of the present invention can be manufactured without a mouse-derived nutritional feeder, special equipment and special scaffolds, and it is very easy to desorb the cell sheet from the medium by a simple physical method without using a cell separator, Portability is possible regardless of the shape and size of the part. Therefore, the cell sheet of the present invention can be useful for the treatment of post-operative mucosal defects such as oral cavity, pharynx, esophagus, and ulcer requiring re-epithelialization.

Подробнее
18-05-2020 дата публикации

Composition for hair restoration comprising induced exosomes

Номер: KR102111964B1
Автор: 이용승
Принадлежит: 주식회사 스템온

세포에 초음파 자극을 제공하고, 세포가 없는 배양 배지에 초음파 자극을 제공하는 단계; 상기 세포와 상기 배양 배지를 혼합하여 일정 시간 배양하는 단계; 및 상기 혼합물에서 엑소좀을 분리하는 단계;를 포함하고, 상기 배양 배지는 배아줄기세포 배지, 모유두세포 배지 또는 모낭줄기세포 배지 중 어느 하나인, 모발 재생 효과를 가진 엑소좀의 제조방법을 개시한다. 이러한 엑소좀의 제조방법은, 다루기 어려운 줄기세포뿐 아니라 손쉽게 얻고 유지할 수 있는 체세포로부터도 초음파 처리라는 간단한 과정을 통해 단시간 안에 높은 수율로 모발 재생 효과를 가진 엑소좀을 수득할 수 있다. 이렇게 수득한 엑소좀은 포함된 각종 인자의 양 및 수 역시 높고, 상기 엑소좀 및 이를 포함하는 조성물은 모발 재생을 유도할 수 있는 다양한 인자가 증가되어 있으며, 엑소좀은 인지질 기반의 막구조를 가져 두피 침투가 용이하여 물질의 전달 효율이 높아 모발 재생을 효과적으로 유도할 수 있고, 합성의약품의 사용으로 나타나는 부작용이 없다는 장점이 있다. Providing ultrasonic stimulation to the cells and providing ultrasonic stimulation to the cell-free culture medium; Mixing the cells and the culture medium and culturing for a predetermined time; And separating the exosomes from the mixture; wherein the culture medium discloses a method for producing exosomes having a hair regeneration effect, which is any one of embryonic stem cell medium, dermal papilla cell medium, or follicular stem cell medium. . The method of manufacturing such exosomes can obtain exosomes having a high rate of hair regeneration in a short time through a simple process called ultrasound treatment, not only from difficult to handle stem cells but also from somatic cells that can be easily obtained and maintained. The exosomes thus obtained also have a high amount and number of various factors included, and the exosomes and compositions containing them have increased various factors capable of inducing hair regeneration, and exosomes have a phospholipid-based membrane structure. It is easy to penetrate the scalp and has high efficiency in transferring substances, so it can effectively induce hair regeneration, and there is no side effect of using synthetic drugs.

Подробнее
22-02-2021 дата публикации

A airtight container for skin cell culture and method for culture of skin cell using the same

Номер: KR102217474B1
Автор: 김완일, 이경하
Принадлежит: 대구한의대학교산학협력단

본 발명은 피부세포 배양용 밀폐용기 및 이를 이용한 피부세포 배양 방법에 관한 것으로, 더욱 자세하게는 개구부가 형성되고, 내부에 배양공간이 마련되는 본체와, 상기 본체에 내부 배양공간으로 관통형성되는 적어도 하나 이상의 통공과, 상기 통공에 결합되는 고무마개가 구비되는 유입부 및, 외주면 가장자리를 따라 상기 본체에 체결되는 걸림쇠가 마련되고, 상기 개구부에 결합되는 캡을 포함하는 세포 배양용 밀폐용기와 세포 배양용 밀폐 용기를 이용한 피부세포 배양 방법에 관한 것이다. 본 발명에 따르면 값비싼 저농도 산소 배양기의 구매 필요 없이 저렴한 피부세포 배양을 이룰 수 있으며, 밀폐능을 향상하여 배양 중 잦은 가스의 이탈을 방지할 수 있기 때문에 고수율로 피부세포를 제공할 수 있다. The present invention relates to an airtight container for culturing skin cells and a method for culturing skin cells using the same, and in more detail, a body having an opening formed therein and having a culture space therein, and at least one formed through the body through an internal culture space An airtight container for cell culture and a cell culture seal including the above through hole, an inlet portion provided with a rubber stopper coupled to the through hole, and a latch fastened to the body along the edge of the outer circumferential surface, and a cap coupled to the opening It relates to a method for culturing skin cells using a container. According to the present invention, inexpensive skin cell cultivation can be achieved without the need to purchase an expensive low-concentration oxygen incubator, and since frequent gas escape during cultivation can be prevented by improving sealing ability, skin cells can be provided with high yield.

Подробнее
31-07-2020 дата публикации

Methods and products for transfecting cells

Номер: CN105420232B
Автор: C·罗德, M·安吉尔
Принадлежит: Factor Bioscience Inc

本发明部分涉及编码蛋白质的核酸;含有非规范核苷酸的核酸;包含核酸的治疗剂;用于诱导细胞表达蛋白质的方法、试剂盒和装置;用于转染、基因编辑和重新编程细胞的方法、试剂盒和装置;以及使用这些方法、试剂盒和装置产生的细胞、生物体和治疗剂。本文公开了使用RNA用于诱导细胞表达蛋白质和用于重新编程和基因编辑细胞的方法。还公开了用于从患者样品中产生细胞的方法、使用这些方法产生的细胞以及包含使用这些方法产生的细胞的治疗剂。

Подробнее
16-04-2002 дата публикации

Methods of making conditioned cell culture medium compositions

Номер: US6372494B1
Принадлежит: Advanced Tissue Sciences Inc

Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. The medium may be conditioned by stromal cells, parenchymal cells, mesenchymal stem cells, liver reserve cells, neural stem cells, pancreatic stem cells and/or embryonic stem cells. Additionally, the cells may be genetically modified. A three-dimensional tissue construct is preferred. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, formulated with a salve or ointment for topical applications, or, for example, made into or added to surgical glue to accelerate healing of sutures following invasive procedures. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.

Подробнее
04-08-2017 дата публикации

A kind of construction method of small intestine 3D organoids research BCRP mediate drug transshipment models and application

Номер: CN107012116A
Автор: 刘明耀, 张磊, 王昕�
Принадлежит: EAST CHINA NORMAL UNIVERSITY

本发明公开了一种小鼠小肠3D类器官用于研究BCRP介导的药物转运模型的构建方法;首先从小鼠小肠消化分离出隐窝,混悬于基质胶后接入细胞培养板中,利用含有Respondin‑1、m‑noggin和m‑EGF三种细胞分化生长因子的ADMEM/F12培养基促进隐窝分化形成3D类器官;然后进行形态学的观察,检测BCRP基因和蛋白表达水平以验证模型理论的可行性;最后采用共孵育的方法,使用BCRP的荧光底物Hoechst 33342及其抑制剂Ko143或YHO‑13177研究BCRP在3D类器官中跨膜转运的活性。本发明首次构建了小鼠小肠3D类器官研究BCRP介导的药物跨细胞膜转运的体外模型,该模型构建方法操作简便、检测高效快速,可广泛应用于BCRP底物和抑制剂的体外筛选。

Подробнее
21-03-2013 дата публикации

Serum-free medium for animal cell culture comprising natural extracts or compounds isolated from them

Номер: KR101245562B1
Автор: 박덕훈, 이종성, 정은선
Принадлежит: 바이오스펙트럼 주식회사

본 발명은 동물세포의 배양을 위한 무혈청 배지에 관한 것으로, 보다 상세하게는 전통적으로 생체외 동물세포 배양에 사용되어 온 기본 배지들에 엉겅퀴 속 식물의 추출물, 오가피 속 식물의 추출물, 스티그마스테롤 및 엔-아세틸갈락토사민으로 이루어진 군으로부터 1종 이상 선택된 물질을 첨가하여 동물세포, 특히 줄기세포를 종래의 혈청 함유 배지보다 우수한 세포 성장율로 배양할 수 있는 동물세포 배양용 무혈청 배지에 관한 것이다. 또한, 본 발명은 상기 동물세포 배양용 무혈청 배지에 첨가된 천연추출물 또는 이로부터 단리된 화합물, 및 상기 배지에서 동물세포를 배양한 후의 배양액의 피부 상태 개선 용도에 관한 것이다. The present invention relates to a serum-free medium for the cultivation of animal cells, more specifically, the extract of thistle plant, the extract of the plant of the genus Ogapi, stigmasterol and in the basic medium that has traditionally been used for in vitro animal cell culture The present invention relates to a serum-free medium for culturing animal cells in which animal cells, particularly stem cells, can be cultured at a higher cell growth rate than conventional serum-containing medium by adding at least one substance selected from the group consisting of en-acetylgalactosamine. The present invention also relates to a natural extract added to the serum-free medium for animal cell culture or a compound isolated therefrom, and a skin condition of the culture solution after culturing the animal cells in the medium.

Подробнее
30-07-2013 дата публикации

Methods and products for reprogramming cells to a less differentiated state

Номер: US8497124B2
Принадлежит: Factor Bioscience Inc

The present invention relates in part to methods for producing tissue-specific cells from patient samples, and to tissue-specific cells produced using these methods. Methods for reprogramming cells using RNA are disclosed. Therapeutics comprising cells produced using these methods are also disclosed.

Подробнее
21-11-2018 дата публикации

Combined chemical and genetic approaches for the generation of induced pluripotent stem cells

Номер: ES2690554T3
Принадлежит: Scripps Research Institute

Un método in vitro o ex vivo para producir células madre pluripotentes inducidas a partir de células no pluripotentes de mamíferos, el método comprende: (a) introducir en las células no pluripotentes de mamíferos (i) uno o más casetes de expresión que comprenden un polinucleótido que codifica un polipéptido Oct4; o (ii) uno o más polipéptidos que comprenden un polipéptido Oct4 exógeno; y (b) poner en contacto las células no pluripotentes de mamífero con un inhibidor de MEK; produciendo de ese modo células madre pluripotentes inducidas. An in vitro or ex vivo method for producing pluripotent stem cells induced from non-pluripotent mammalian cells, the method comprises: (a) introducing into non-pluripotent mammalian cells (i) one or more expression cassettes comprising a polynucleotide encoding an Oct4 polypeptide; or (ii) one or more polypeptides comprising an exogenous Oct4 polypeptide; and (b) contacting non-pluripotent mammalian cells with an MEK inhibitor; thereby producing induced pluripotent stem cells.

Подробнее
19-07-2016 дата публикации

Chemical approaches for generation of induced pluripotent stem cells

Номер: US9394524B2
Принадлежит: Scripps Research Institute

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Подробнее
05-07-2018 дата публикации

Combined chemical and genetic approaches for generation of induced pluripotent stem cells

Номер: JP2018104473A
Принадлежит: Scripps Research Institute

【課題】哺乳動物細胞において多能性を誘導するための低分子の特定および使用、ならびに多能性を誘導する方法の提供。【解決手段】(a)i)Octポリペプチドをコードするポリヌクレオチド、Klfポリペプチドをコードするポリヌクレオチド、およびSoxポリペプチドをコードするポリヌクレオチドを含む1つまたは複数の発現カセット;またはii)外因性Octポリペプチド、外因性Soxポリペプチド、および外因性Klfポリペプチドを該哺乳動物非多能性細胞に導入する工程;ならびに(b)該哺乳動物非多能性細胞と、GSK3インヒビター、MEKインヒビター、およびTGFβ受容体/ALK5インヒビターを接触させる工程を含む、方法。【選択図】図1

Подробнее